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Clinical treatment options for articular cartilage repair are progressing with the 
incorporation of synthetic matrices alongside current autologous chondrocyte 
implantation techniques.  This work explores mechanical and mass transport design of 
potential matrices.  Solid freeform fabrication (SFF) is used to create highly reproducible 
scaffolds with precise structural features in order to explore the mechanical potential of 
3D designed poly(ε-caprolactone) (PCL) and poly(glycerol sebacate) (PGS) scaffolds, 
and to examine the effects of a designed physical property, permeability, for cartilage 
regeneration.   
 
Our first aim explores the potential of PCL and PGS scaffolds to provide temporary 
mechanical function within a tissue defect.  We find that PCL mimics the viscoelastic 
nature of cartilage; however its stiffness properties cannot be changed through alterations 
in molecular weight or melting temperature.  Fabricated into the architectures explored, it 
has aggregate modulus (HA) values within the correct magnitude, but higher than native 
cartilage.  Furthermore, we demonstrate the importance of mechanically testing PCL 
scaffolds at physiological temperatures and we quantify their contraction in polar 
environments.   
 
 xv
Poly(glycerol sebacate) has never been used for cartilage tissue engineering.  We 
characterize how variations in the molar ratios of glycerol to sebacic acid (during pre-
polymer synthesis) or variations in curing time can be used to change the stiffness of 
PGS,  enabling fabrication of scaffolds with a wide range of architectures (designed for 
optimal tissue regeneration) that all support in vivo loads.  Chondrocytes seeded onto 
PGS produce cartilaginous matrix and express cartilage specific genes similar to or better 
than cells cultured on PCL, showing the biocompatibility of PGS for cartilage 
applications for the first time.  
 
Our second aim looks at enhancing cartilage regeneration by optimizing scaffold 
permeability.  We show that chondrocytes prefer a lower permeable scaffold that mimics 
the natural environment of native tissue, producing significantly more matrix and 
increased expression of cartilage specific markers. Bone marrow stromal cells (BMSCs) 
display the opposite trend, favoring a higher permeable environment for chondrogenic 
differentiation, as displayed through collagen 2 to collagen 1 expression, suggesting that 
increased access to chondrogenic induction factors in media is more important to these 






1.1 Problem Statement 
As early as 1743 Hunter 1 observed that cartilage, “once destroyed, is not repaired.” Over 
250 years later, there are few methods used to repair cartilage that can restore a durable 
articular surface to lesions caused by trauma or evolved during the course of diseases 
such as osteoarthritis.  Even the methods used clinically are not completely successful at 
restoring the native environment of cartilage over an extended period of time.   In the 
U.S. alone, musculoskeletal conditions are estimated to cost over $300 billion annually.  
Musculoskeletal impairments are the number one category of reported chronic 
impairment and rank number one in visits to physicians’ offices (102.5 million visits per 
year), with 36.9 million Americans (one in three) incurring a musculoskeletal injury 
every year.  Worldwide, musculoskeletal conditions are the most common cause of 
physical disability and severe long-term pain.2   It is for reasons like this that George W. 
Bush declared 2002-2011 as the Bone and Joint Decade.  
 
1.2 Articular Cartilage Disease and Damage 
Most all forms of disease and damage to articular cartilage result in osteoarthritis, a type 
II collagen disorder.  Aging is the primary cause of damage to articular cartilage, where 
everyday use leads to flaking and formation of crevasse in its surface, commonly termed 
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“primary osteoarthritis”.  Secondary causes of osteoarthritis include obesity, trauma, 
congenital defects that result in abnormal joints at birth, gout, diabetes, or hormone 
disorders.  Traumatic injury to articular cartilage can result from abnormal rotation of a 
joint (such as twisting injuries that usually result in anterior cruciate ligament rupture) or 
from forceful impact.3   Evidence shows that each of us may have a genetic 
predisposition that regulates our bodies’ response to these factors, determining the extent 
of osteoarthritis that incurs.4    
 
1.3 Clinical Treatment Options 
The primary reason for this tissue’s dramatic inability to regenerate and repair itself 
stems from its isolation from the rest of the body.  Cartilage lacks blood vessels, 
lymphatic vessels and nerves.  Nutrition of cartilage relies on diffusion of nutrients from 
the synovial fluid that encapsulates articular joints.5  There are a number of clinical 
treatment options for the repair of articular cartilage, and technology in this field is 
rapidly advancing.  Over the past decade (1998-2008), the three most commonly 
performed procedures were microfracture, mosaicplasty, and autologous chondrocyte 
implantation (ACI). During microfracture, damaged or unstable cartilage is debrided, or 
cleaned away, and small holes are poked into the subchondral bone, allowing marrow 
elements to diffuse into the repair site.  These marrow elements contain cells which can 
differentiate into chondrocytes, and produce a matrix that matures over time to fill the 
defect.  Unfortunately, most of the repair tissue is fibrocartilage, which possesses a 
different collagen composition and, therefore, different biomechanical properties than 
native tissue.  The microfracture technique is most effective for small articular defects (< 
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4cm2), but normal cartilage composition and structure are never actually restored and 
tissue inevitably undergoes progressive degeneration.6    
 
Mosaicplasty, or osteochondral autografting, is a treatment option that replaces damaged 
or missing cartilage with an osteochondral (bone + cartilage) plug taken from a non-load 
bearing site.   Although this technique repairs the defect with already mature and healthy 
cartilage, it requires sacrificing healthy cartilage in one location in order to restore the 
damaged area.  It can also be difficult for surgeons to accurately fill defects in terms of 
size and natural contour using mosaicplasty.6   
 
Finally, there is a promising “tissue engineering” technology making its mark in the area 
of articular cartilage repair termed autologous chondrocyte implantation (ACI).  The 
repair system, named Carticel®, is available through Genzyme Corporation.  It is a two 
stage process in which a small biopsy of a patient’s healthy cartilage is removed and 
digested.  Chondrocytes extracted from the tissue during digestion are grown in culture 
for implantation back into the patient in the second stage. Currently, the cultured cells are 
simply injected under a periosteal patch that covers the defect site.  These autologous 
cells are able to produce cartilaginous matrix, eventually replacing the articular defect 
with new cartilage.   A clinical trial by Peterson et al.7  examined the outcomes of ACI in 
isolated femoral condyle lesions, multiple femoral condyle lesions, including lesions of 
the trochlea and lesions in combination with patellar lesions (kissing lesions), 
osteochondritis dissecans lesions, patellar lesions, and femoral condyle lesions with 
anterior cruciate ligament reconstruction.  All chondral defects were classified as 
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moderate to large (1.3-12.0 cm2) full thickness lesions. Two to nine-year outcome 
measures show excellent repair in isolated femoral condyle lesions, but decreased success 
for those with multiple lesions or patellar lesions.   
 
Improvements to ACI, termed “second generation” techniques, incorporate matrices to 
help retain cells and eliminate the need for a periosteal flap.6-8   There are currently three 
“second generation” technologies being used clinically in relatively large numbers of 
patients: Matrix-induced autologous chondrocyte implantation (MACI®), Hyalograft 
C®, and Bioseed®.  The scaffold materials used in these technologies are a bilaminate 
collagen, a hyaluronic acid-based scaffold, and a composite PLA-PGA polymer fleece, 
respectively.  Although these treatment options show promising results, none of them 
have been released in the United States.  NeoCart®, a bovine collagen gel/sponge 2nd 
generation ACI treatment, is however, entering a phase two trial in the United States that 
will compare its safety and efficacy versus microfracture.9  
 
1.4 Tissue Engineering Improvements 
Although ACI and 2nd generation ACI treatments are proving to be a promising technique 
and are paving the way for clinical use of tissue engineering treatment of articular 
cartilage defects, there are a number of tissue engineering principles that can still be 
incorporated into this repair system.  Tissue engineering strategies aim to combine three 
components: cells, biomaterials, and growth factors, in order to repair damaged tissue.  In 
terms of the cells used, advances can be made to utilize cells that are easier to obtain and 
do not require the sacrifice of healthy cartilage. Cell types currently being explored for 
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these purposes include bone marrow stromal cells10-13  and pre-adipocytes.14-18   Growth 
factors are also being explored for supporting chondrogenesis.  These include 
transforming growth factor beta (TGF-β), bone morphogenetic protein (BMP), basic 
fibroblastic growth factor (bFGF), and insulin-like growth factor-1 (IGF-1). Their effects 
are being studied for multiple cell types and various conditions. 11, 19   Further advances 
can also be made to optimize the final component of the tissue engineering triad, the 
matrix (scaffold) being implanted along with the cells and growth factors.  Not only 
should the scaffold help to retain cells and deliver growth factors, but it should provide 
biomimetic mechanical properties, and optimal mass transport properties to enhance 
cartilage tissue regeneration. 
 
1.5 Goals of This Thesis 
This thesis will focus on two primary goals for design of more advanced cartilage tissue 
engineering scaffolds for such repair modalities (illustrated in Figure 1.1):  
 
1.  To provide temporary mechanical function within a tissue defect through 
incorporating a biodegradable scaffold that initially mimics target stiffness 
properties of native cartilage  
 
2.  To enhance tissue regeneration through providing optimal mass transport 





Goal #1: Providing Mechanical Support 
Hypothesis: The mechanical properties of tissue engineering scaffolds can be controlled 
through biomaterial processing parameters in order to create 3D-designed scaffolds that 
provide adequate support to developing tissue. 
  
Cartilage helps to distribute loads between opposing bones in a synovial joint.  Due to its 
low friction and wear, and its compliance, it permits smooth motion and reduces contact 
stresses at joint surfaces. In order to do this properly, cartilage is made up of 
chondrocytes embedded within an extracellular matrix that is composed of collagen 
(~60% of the dry weight), proteoglycans (~25% dry weight), and other proteins and 
glycoproteins (~15% dry weight). Together, these substances maintain the proper amount 
of water within the matrix, and result in the unique mechanical properties of the tissue.5    
 
In order to achieve the first goal, we must define the quantitative measures we wish to 
attain.  Amongst the generally accepted requirements that an ideal tissue engineering 
scaffold will be biocompatible, noncytotoxic, biodegradable, able to support and hold 
cells, permeable, reproducible, readily available, and versatile for full and partial 
thickness lesions, lies the requirement that it must also be mechanically stable.9   Here, 
we focus on the requirement that a scaffold should have stiffness values similar to native 
articular cartilage.  By matching these target stiffness values, the scaffold will withstand 
physiological loading, produce the mechanical tension generated within the cell 
cytoskeleton critical for cell shape and function, and mimic stiffness values that may 
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affect cell to cell contacts and aggregation.20   Furthermore, when the scaffold (with or 
without tissue) is implanted into a defect site, there should be no stiffness differences 
between healthy cartilage and regenerating tissue, which may cause fibrous tissue 
formation, elevated levels of strain in the adjacent cartilage, and accelerated degeneration 
of the tissue.21   Functions of viscoelasticity and nonlinear elasticity, both measures of 
material stiffness, will be examined. 
 
Numerous materials have been used in order to create scaffolds for tissue engineering, 
reviewed in depth in Chapter 3.  The two materials we explore in this thesis are poly(ε-
caprolactone) (PCL) and poly(glycerol-sebacate) (PGS).  We explore the elastic 
properties of these materials using confined and unconfined compression testing, and 
determine if altering their processing parameters can provide initial stiffness properties of 
optimally designed scaffolds (goal #2) within the ranges of native articular cartilage.  
 
Goal #2: Providing Optimal Mass Transport  
Hypothesis: Mass transport properties of scaffolds affect matrix production by 
chondrocytes and cellular differentiation of bone marrow stromal cells. 
 
The mass transport property that we study here is hydraulic permeability, the ease with 
which fluid flows through a tissue, or in this case a scaffold, when driven by a pressure 
gradient.  Many groups have measured the permeability of bovine cartilage 22-28  in order 
to characterize the tissue or quantify changes due to diseases or injuries.  In comparison 
to other musculoskeletal tissues, the permeability of cartilage is very low.  And, an 
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increase in the permeability of osteoarthritic cartilage results in greater and more rapid 
deformation of tissue.29, 30   When designing 3D scaffolds, some groups state their 
hypothesis that providing maximum porosity (and hence, increased permeability) will 
promote tissue ingrowth.31  Though this may be true for bone tissue engineering, it must 
be understood that for cartilage tissue engineering, this increase in permeability 
contradicts the clinical finding that native healthy cartilage exhibits relatively low 
permeability. 
 
As reviewed in Chapter 4, there are a number of studies that examine the effects of 
scaffold architectures on cartilage tissue regeneration, with no consensus on how the 
structural properties of pore size, porosity, and interconnectivity affect chondrogenesis.  
Li et al., however, prove that none of these properties can be used individually to 
describe mass transport.  Instead, they suggest that “one conventional physical 
parameter”, permeability, be used as a description of the complicated porous structures 
encountered in the process of tissue engineering.32  In this work, we will examine how 
the physical property of permeability, as described by Darcy’s law, affects chondrocytes 
or bone marrow stromal cells seeded onto PCL scaffolds, cultured in vitro, with the 
hypothesis that this parameter can be used to more accurately predict the effects of 
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“Ongoing research into new scaffold materials and designs will surely lead to better 
treatment of patients with cartilage injuries.”9
 
Figure 1.1 Flow diagram of dissertation goals.   
 
 “Second generation” autologous chondrocyte implantation will incorporate a scaffold, or 
matrix material, that will improve cell retention and provide mechanical stability, while 
also enhancing cartilage regeneration through physical and biochemical environmental 
ques.  There is a wide array of scaffold components to be optimized for this repair system 
including the ones examined here.  Research in this field will also consider surface 
modifications, growth factor delivery, and the ways in which degradation profiles affect 
tissue regeneration.   Here we show that PCL and PGS scaffolds are two promising 
materials that can provide initial scaffold stiffness values within the ranges of articular 
cartilage.  We then show that the permeability of a scaffold significantly affects the 
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differentiation of bone marrow stromal cells and cartilage matrix deposition by 
chondrocytes, and is an important consideration when designing scaffolds for cartilage 
tissue engineering. 
 
1.6 Contents of Dissertation 
Chapter two introduces the tissue we aim to repair, articular cartilage, and the structural 
and biomolecular components assessed in regenerated tissue.  Keeping in mind our first 
goal, Chapter 3 introduces how biomaterials can be used to provide mechanical stability 
to damaged cartilage, including a review on the mechanical properties of native cartilage, 
materials that have been previously used for this purpose, and an introduction to Poly(ε-
caprolactone) (used in Chapter 5) and Poly(glycerol-sebacate) (used in Chapter 6).  The 
second goal of this dissertation is to enhance regeneration of cartilage through optimizing 
the mass transport property of permeability.  Chapter 4 explains the rationale for studying 
this physical property with regards to cartilage tissue engineering.  Chapter 5 
characterizes the mechanical properties of melt-cast PCL for cartilage applications. 
Chapter 6 introduces the use of PGS in cartilage tissue engineering, characterizing 
mechanical properties that are adjustable through processing parameters, and showing 
that it is biocompatible with chondrocytes.  Finally, Chapter 7 reveals that the 
permeability of scaffolds significantly affects GAG production by chondrocytes and 
differentiation of bone marrow stromal cells in 3D designed scaffolds, and should be 
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Articular cartilage, hyaline cartilage that covers the ends of long bones of synovial joints, 
is a unique and complex tissue.  The intricate macromolecular structure of this tissue 
results in its remarkable ability to absorb everyday forces put on joints and to rebound 
once those forces are removed.  The entire matrix that provides this function is 
synthesized and maintained by a sole cellular component, the chondrocyte.  The matrix 
has an assistive counterpart, the synovial fluid it is bathed in, which provides frictionless 
gliding between articulating surfaces during locomotion.  Together, these components 
make up the white, translucent, shiny tissue that coats our joint surfaces and provides our 
skeleton with extraordinarily durable load-bearing capacity.1   
 
Although it may seem simple, one cell type that synthesizes and maintains a matrix, plus  
synovial fluid that nourishes it and allows it to glide against itself, cartilage is extremely 
difficult to repair both through the natural repair mechanisms of our body, and with the 
aid of modern medicine.  The absence of natural repair mechanisms, as seen in other 
tissues, results from the tissues avascularity and hypocellularity.  Cartilage receives 
nourishment by diffusion of nutrients from the synovial fluid, in comparison to more 
metabolically active tissues that are infiltrated with blood vessels supplying continual 
nutrients to entire organs. Furthermore, the cells responsible for synthesis and 
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maintenance of the tissue are rather quiescent and only comprise 1-2% of the tissue 
volume.  Even in healthy cartilage, the turnover of extracellular matrix (ECM) 
components is slow, so when faced with the challenge to restore damaged tissue there is 
no fast mechanism to rely on. From a tissue engineering point of view, the difficulty in 
restoring this damaged tissue is further implicated with the heterogeneity of the tissue, 
which consists of superficial, middle, deep and calcified layers designated by changes in 
chondrocyte shape (flattened to rounded) and variations in collagen fiber thickness and 
orientation (thin, tangential to thick, radial bundles) throughout.  
 
All of these intricacies lead to a wide array of qualitative and quantitative approaches to 
evaluating tissue engineered cartilage, including histological, biochemical, mechanical 
and molecular genetic measures.  After introducing the embryonic development of 
cartilage, we review the biochemical and molecular genetic measures we will use during 
this work, saving intricacies of mechanical measurements for full review in Chapter 3.  
When regenerating articular cartilage in vitro, we will assess outcomes by quantifying 
matrix production by cells and by measuring the cellular expression of genes that relate to 
chondrogenic differentiation.  Specifically, in this work, we measure the amount of 
sulfated-glycosaminoglycans (sGAGs) produced by cells seeded within a scaffold and we 
also quantify the cellular mRNA expression of aggrecan, collagen 1, and collagen 2.  In 





2.1 Embryonic Development of Cartilage 
Cartilage is formed from the condensation and differentiation of skeletal progenitor cells 
(cells that can form more than one skeletal cell type and tissue type in embryos and in 
adults).  The first step in formation of cartilage-type cells is condensation of these 
skeletal progenitor cells.  In cartilage tissue formation, the condensation consists of cells 
that are ALL chondrogenic and are ALL at the same stage of development, 
communicated via GAP junctions. At the point of cellular condensation, cartilage specific 
genes including heparin-sulfate and chondroitan sulfate proteoglycans are expressed, 
allowing differentiation between these cartilage-forming clusters and other skeletal 
tissue-forming groups (such as bone).  Once this cellular condensation attains a critical 
size, genes controlling proliferation are down-regulated, and genes associated with 
differentiation are up-regulated.  Cells differentiate based on a cocktail of growth factors 
and hormones that direct the cellular condensation down a chondrogenic pathway, in 
which the cells become chondrocytes and begin producing and maintaining cartilage. 2  
One goal of this work is to differentiate bone marrow stromal cells (derived from bone 
marrow aspirates) down a chondrogenic lineage through culturing them in vitro in 
chondrogenic media on 3D-designed scaffolds.  When obtained from the bone marrow 
stroma, these cells represent a heterogenous population of cells that can be differentiated 
into bone, cartilage, adipocytes and hematopoietic supporting tissues.3   Here we focus on 
how differences in scaffold permeability may affect chondrogenic differentiation of bone 




2.2 Cartilage Extracellular Matrix: Glycosaminoglycans 
The main matrix molecules of cartilage are proteoglycans, making up about 3-10% of the 
wet weight and ~25% of the dry weight of hyaline cartilage.4   They consist of a core 
protein to which one or more glycosaminoglycans (GAGs) are attached (see Figure 2.1).  
These negatively charged aggregates attract water molecules into the tissue, giving 
cartilage its resistance to compression and resilience upon unloading of the tissue.  The 
main types of GAGs found in articular cartilage are chondroitin sulfate, keratin sulfate 
and hyaluronic acid.  The first two, being sulfated, are commonly measured through a 
biochemical assay in order to show the production and deposition of extracellular 
cartilaginous matrix.  They are attached to a core protein, which is attached to a backbone 
of hyaluronic acid through a link protein.  The type of GAG is determined by the 
repeating disaccharide unit labeled “A and B” in Figure 2.1.  Although not depicted here, 
these chains are arranged on the core in pairs, called doublets, where in the case of 
chondroitan sulfate, the chains are separated by less than ten amino acid residues, and the 
doublets are separated by about thirty-five residues.5   Proteoglycans are both synthesized 
and metabolized by chondrocytes, regulated such that adult cartilage maintains consistent 




Figure 2.1  A detailed look at the glycosaminoglycans of articular cartilage6  (portion of figure used 
with permission from Elsevier).    
 
Developmentally speaking, changes in size, chemical composition and structure of 
proteoglycan monomers occur between fetal development and maturity of the cartilage.  
Proteoglycans from fetal and immature cartilage are larger, more uniform in size, and 
contain more chondroitin sulfate and less keratan sulfate than those of mature cartilage.  
Although the basis for these changes is unclear, it could help to explain the deterioration 
of articular cartilage during aging, and help to determine if some people are predisposed 
to development of osteoarthritis (OA) based on the maximum length of their 
proteoglycan chains during fetal development.7  
 
2.3 Cartilage Gene Expression 
Proteins expressed in cartilage can be measured at the transcriptional (messenger-RNA, 
mRNA) or translational (protein) levels.  Here we measure the mRNA expression of 
genes that code for cartilage specific proteins (collagen 2 and aggrecan) and a gene that 
enables us to detect chondrogenic dedifferentiation or bone marrow stromal cell 
differentiation, relative to collagen 2 levels (collagen 1).  
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2.3.1  Aggrecan 
Aggrecan is the main proteoglycan found in cartilage, and is a typical marker of 
differentiated chondrocytes.  It is a structural proteoglycan, meaning that it helps the 
extracellular matrix (ECM) maintain its highly hydrated state.2 Messenger-RNA 
expression of aggrecan can be detected in periosteal cells immediately before they 
differentiate into chondrocytes.2   Aggrecan molecules generally exist as aggregates, 
made up of a central hyaluronic acid (HA) backbone with up to 100 aggrecan molecules 
attached by link proteins.  Fully intact, these aggregates have a molecular mass of 
210,000, however due to regular cleavage by aggrecanases and metalloproteinases 
(MTPs) they rarely exist at this length.8  Upregulation of aggrecanases and MTPs are 
seen in osteoarthritis, resulting in increased cleavage of the core protein and cleavage of 
HA.  This increase in cleavage causes a decrease in charge density of the tissue, and a 
decrease in aggregate size, resulting in deterioration of cartilage.9, 10 Messenger-RNA 
expression of aggrecan levels (normalized to GAPDH) in native tissue vary widely, from 
reports on porcine cartilage explants of about 80 8 to reports on healthy human articular 
cartilage ranging from .82 to 1.8.11, 12  
 
2.3.2  Collagen 2 
Type two collagen is the major fibrillar collagen of articular cartilage, accounting for 90-
95% of the overall collagen content.13   This gene is localized to cartilage, the vitreous of 
the eye, the nucleus pulposus of intervertebral discs and the embryonic chick primary 
corneal stroma.  It provides cartilage with its tensile strength and immobilizes 
proteoglycans within its matrix. It can be used as a sensitive marker for chondrogenic 
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differentiation of precursor cells, and may coincide with an irreversible commitment to 
chondrogenesis.  Defects in type II result in premature osteoarthritis.2    Collagen II 
expression as measured by qtPCR on native tissue also shows high variation, with 
normalized values ranging from .2 to 94.10, 12  
 
2.3.3  Collagen 1 
Collagen 1, generally associated with bone, is found in small amounts in human articular 
cartilage and increasing amounts in fibrocartilages, presumably contributing to the 
functional requirements of the tissues.  However, it has been reported to account for a 
surprisingly high 11.6% of the collagenous component of porcine cartilage.14   Its level of 
expression is commonly used as a marker of chondrocyte dedifferentiation.  As a ratio, 
the expression of collagen 2: collagen 1 is termed the “differentiation index” with a larger 
value correlating with a more chondrocytic genotype, and a lower value correlating with 
more fibroblastic gene expression.11   Interestingly, Kosher et al. show that collagen 1 
mRNAs are present during limb development, even when the protein is not produced in 
detectable amounts.15   Osteoarthritic cartilage contains increased levels of collagen type 
1, decreasing its ability to bind GAG.2   Collagen 1 expression in native cartilage ranges 
from reports of none being expressed 12 to 17 (as a % of GAPDH).10  
 
2.3.4  Effects of monolayer and 3D culture on gene expression  
Chondrocytes are difficult to culture in monolayer, where they quickly dedifferentiate.  
This is shown genetically through decreases in aggrecan and collagen 2: collagen 1 
expression during monolayer culture and passaging.16-18    In 3D culture, chondrocytes 
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behave more favorably, where they show increased aggrecan and collagen 2: collagen 1 
ratios versus cells cultured in monolayer, and increases over time.16, 19  A report on the 
chondrogenic differentiation of BMSCs in pellet culture and 3D hydrogels (similar to the 
methods used in this work), demonstrate that aggrecan and collagen 2 expression can be 
maintained, or even increased under 3D conditions in chondrogenic media.20, 21  
 
Although it seems useful to compare quantitative measures of these genes expressed in 
tissue engineered cartilage to levels found in native cartilage, upon review, these 
quantitative values vary quite widely.  It is more accurate to compare expression levels 
within one study relative to time or in this case, scaffold designs.  In order to relate 
expression levels of these genes in scaffolds to initial expression levels of the cells 
utilized, a sample of chondrocytes and bone marrow stromal cells were set aside just 
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CHAPTER 3 
BIOMATERIAL SCAFFOLDS FOR CARTILAGE APPLICATIONS 
 
Polymer scaffolds will play a major role in treating cartilage defects, deterioration, and 
damage.  There are a number of natural and synthetic materials that have been used to 
create scaffolds for cartilage tissue engineering and a variety of fabrication methods that 
can be used to process these materials into scaffolds for cartilage regeneration. It is 
generally accepted that the requirements for the ideal scaffolds include that the construct 
is biocompatible, noncytotoxic, biodegradable, able to support and hold cells, permeable, 
mechanically stable, reproducible, readily available, and versatile for full and partial 
thickness lesions.1   Here, we focus on the requirement that a scaffold should have 
mechanical properties, particularly stiffness values, similar to the cartilage tissue being 
regenerated.  By matching target stiffness values of articular cartilage, the scaffold will 
withstand physiological loading, produce the mechanical tension generated within the 
cell cytoskeleton critical for cell shape and function, and mimic stiffness values that may 
affect cell to cell contacts and aggregation.2   Furthermore, when the scaffold (with or 
without tissue) is implanted into a defect site, there should be no stiffness differences 
between healthy cartilage and regenerating tissue.  Differences in tissue mechanical 
properties may cause fibrous tissue formation, elevated levels of strain in the adjacent 
cartilage, and acceleration of degeneration of the tissue.3    
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Figure 3.1.  Schematic diagram4 displaying the ideal profile for a tissue engineering scaffold, where 
generation of tissue compliments molecular weight and mass loss of a scaffold, resulting in 
mechanical properties that continually match those of native tissue (figure used with permission from 
Elsevier). 
 
The repair strategy that this work aims to achieve is described by Hutmacher4  as 
“strategy 1” in which “the physical scaffold structure supports the polymer/cell/tissue 
construct from the time of cell seeding up to the point where the tissue transplant is 
remodeled by the host tissue.”  A schematic of this strategy can be seen in Figure 3.1.  
Although polymer scaffold mechanical properties can be changed through variations in 
porosities and pore size to achieve the required initial mechanical properties, these 
changes also affect tissue regeneration in complicated manners.  The ability to match 
initial properties through changes in bulk material properties is an advantageous route to 
pursue.   
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3.1 Mechanical Properties of Native Tissue  
Cartilage is made up of chondrocytes embedded within an extracellular matrix that is 
composed of collagen (~60% of the dry weight, dw), proteoglycans (~25% dw), and 
other proteins and glycoproteins (~15% dw).5   Together, these substances maintain the 
proper amount of water within the matrix, which confers its most significant functional 
property: its unique mechanical properties.6  
 
Articular cartilage exhibits a viscoelastic, shock absorbing response to load.  Its distinct 
mechanical properties stem from the biphasic nature of the tissue, in which a solid (the 
cartilage matrix) and a liquid (synovial fluid) have a unique interplay with one another.  
When loaded, the negatively charged proteoglycans in the solid matrix of cartilage are 
compressed together, increasing their repulsive nature to one another, and resulting in a 
resilient response. At the same time, when deformed, synovial fluid flows through the 
tissue in order to equalize pressure differences.  Not only do the mechanical properties 
provide the proper functional abilities for load bearing, the interplay between the solid 
and fluid phases is also implicated in the proper development and maintenance of the 
tissue.  The matrix acts as a signal transducer for cells, where loading creates mechanical, 
electrical and physiochemical signals that help direct chondrocyte synthetic and 
degradative activity.7  
 
The mechanical property that this work focuses on matching is the equilibrium aggregate 
modulus (HA) of native articular cartilage. In order to proceed with this aim, we must 
define the target values that we wish to achieve. The term “aggregate modulus” and 
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“equilibrium modulus” are synonymous, defined as the equilibrium stress divided by the 
equilibrium strain in stress relaxation.  The term quantifies the stiffness of the tissue 
when all fluid flow has ceased, taking into account the interactions of fluid and solid 
phases affected by applied loads. The higher the aggregate modulus, the less the tissue 
deforms under a given load.8   The aggregate modulus of articular cartilage depends on 
age, anatomic location, and mechanical testing procedures.  Table 3.1 reviews the HA 
values of articular cartilage as measured in confined compression.  Values for human 
cartilage are from patients that have undergone total hip replacements due to femoral 
head fractures.  It is important to note that higher stiffness values of these patients is most 
likely due to changes in the loading environment of articular cartilage that covers 
osteoporotic subchondral bone.  The generally accepted range of HA values for healthy 













Table 3.1.  Mechanical properties of articular cartilage as measured in confined compression. 





average ± stdev or 
range) 
fetal Knee (femoral condyle) Knee (medial side) 
0.089 ± 0.032 9  
0.11 ± 0.03 10  
1-3 weeks Knee (femoral condyle) Knee (medial side) 
0.197 ± 0.0219  
0.27 ± 0.0210  
3-4 weeks Knee (patellar groove) 0.79-1.72 11  
6 months Knee 0.49 ± 0.05 (in PBS)*
12  
0.64 ± 0.16 (in PVP)* 12 
18-24 months Hip (femoral head) Knee (medial side) 
.57-1.01 13  




Shoulder (glenoid surface) 
Knee (femoral groove) 
0.40 ± 0.1414  




N/A Hip 0.840* 16  
16-85 years Knee (patella) 0.79 ± 0.36 17  





65-90 years Hip (femoral head) 2.22 ± 0.6513  
PBS = phosphate buffered saline 
PVP = polyvinilpyrolidone in deionized water 
* dynamic mechanical analysis 
 
 
3.2 Controlling Scaffold Stiffness for Cartilage Applications  
 
A variety of natural and synthetic materials show favorable outcomes for use as scaffolds 
in cartilage tissue engineering.  Throughout this section, the reference to “scaffolds” is 
not inclusive of natural material matrices such as agarose, alginate, hyaluronic acid, 
gelatin, fibrin glue, collagen derivative and acellular cartilage matrix, as they have been 
shown to have mechanical properties that are both difficult to control and too weak to 
support mechanical loads in an articular site.  Rather, this section will focus on synthetic 
biomaterials, as they offer increased control and modification of scaffold properties.19   
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Synthetic polymers used for cartilage tissue engineering include polyglycolic acid (PGA), 
PGA+trimethylene carbonate, polycaprolactone, poly(ethylene oxide 
terephthalate)/poly(butylene terephthalate) (PEOT/PBT), poly(ethylene glycol) (PEG) 
cross-linked with polyrotaxane, silkworm and spider silk, tantalum, poly(lactic-co-
glycolic acid) (PLGA), poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) (PHBHHx), 
polylactic acid (PLLA), and poly(propylene fumarate) (PPF).20-35   Materials reported 
have shown favorable outcomes as measured by GAG production by chondrocytes or 
differentiation of bone marrow stromal cells seeded into them and cultured in vitro or in 
vivo.  However, long-term studies using human cells are rarely to never performed.   
 
Many synthetic scaffolds show promising stiffness values that fall within the ranges of 
native cartilage tissue (.089 MPa-2.22 MPa, as seen in Table 3.1).  Materials that have 
been fabricated into scaffolds with desirable stiffness values include PGA-PLLA meshes 
(0.919 MPA),33  collagen-coated PLA microcarriers suspended in chitosan hydrogel 
(0.87-2.15 MPa),34  chondroitan-sulfate-grafted PLLA (1.441 MPa),35  PEOT/PBT 3D 
designed scaffolds (0.04-8.0 MPa dependant on porosity and architecture or 0.15-6.33 
MPa dependant on copolymer compositions),36, 37  PGA fiber meshes (0.138-0.199 MPa 
dependant on pore size),38  fiber deposited PEGT/PBT block co-polymer scaffolds (0.05-
2.5 MPa dependent on deposition parameters),39  and  photocrosslinked PEG scaffolds 
crosslinked with PLA (0.006MPa-0.5 MPa dependant on % macromer).40   Synthetic 
scaffolds that have reported stiffness higher than desired include a blend of three 
copolymers of 50:50 poly(d,l)-lactide coglycolide (8.5 MPa),41  and thermally induced 
phase separated PLLA, which when dry has values within the desired range (2.05 MPa), 
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but when wet or agarose-gel laden increases in stiffness (3.38 MPa and 5.16 MPa 
respectively).42   On the other hand, there are also scaffolds reported with stiffness values 
below the ranges of native cartilage, including PGA unwoven meshes (.008 MPa),43  
porous polyurethane sponges (.023 MPa),44  non-woven, coagulated, or salt leached silk 
fiber scaffolds (~0.05 MPa),28  and porous PVA-PLGA scaffolds (0.087-0.102 MPa).45  
Mechanical properties pertaining to use of PCL for cartilage applications are discussed 
later in this chapter. 
 
Synthetic materials offer increased control and variation over scaffold mechanical 
properties.  Solid freeform fabrication (SFF) of scaffolds is an ideal method that can 
exploit this control and variability.  In terms of matching mechanical properties of 
scaffolds to native tissue properties (goal #1), SFF grants the ability to accurately 
determine mechanical properties of scaffold designs through finite element analysis, 
simply by knowing the bulk material properties of polymers that can be used for scaffold 
fabrication.  It is also ideal for exploring the way that mass transport will affect tissue 
regeneration (goal #2) as it allows for precise design and excellent reproducibility of 
specific architectures.  Aside from the goals of this work, SFF provides many other 
benefits for creating scaffolds for cartilage tissue engineering.  On a global scale, SFF 
enables design and fabrication of anatomically shaped scaffolds.  For osteochondral 
applications, it allows the creation of biphasic scaffolds that incorporate multiple 
geometries into a single scaffold,46, 47  allowing for in-growth of multiple tissues into a 
single structure.  Particularly beneficial for articular cartilage applications, it allows the 
creation of different zones of organization within a single tissue compartment.  Native 
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cartilage exhibits a superficial zone (elongated and flattened chondrocytes arranged in 
fascicles parallel to the surface), an intermediate zone (round chondrocytes randomly 
distributed), and a deep zone (chondrocytes arranged in short columns).48   SFF allows 
the incorporation of distinctly designed architectural zones into a single scaffold, 
allowing recapitulation of this native organizational scheme. More locally, SFF allows 
for precise control of internal architectures, such as pore size, pore shape, 
interconnectivity and porosity.  This increased control, over conventional methods, 
creates excellent reproducibility of intricate architectures, providing obvious benefits to 
basic science research and clinical applications.  Within the field of tissue engineering 
research, it enables us to study how various scaffold architectures may affect cell 
infiltration, mass transport of nutrients and metabolic waste, and thereby influence tissue 
regeneration.  Several authors have reviewed the advantages of SFF techniques currently 
in use for a wide array of other applications.4, 49-52   In this thesis, we use SFF methods to 
fabricate scaffolds from two materials in order to achieve our first design goal of 
matching the mechanical properties of a 3D designed solid-freeform scaffolds to target 
modulus properties of native tissue. The two materials explored are a widely used 
synthetic polymer, polycaprolactone (PCL) and a more recently developed polymer, 
poly(glycerol sebacate) (PGS).  We then use SFF to create precise, reproducible scaffolds 
with designed permeability in order to study the effects of this physical parameter on 





3.3 Poly(ε-caprolactone)  
PCL is formed when ε-caprolactone is heated and undergoes a ring-opening 
polymerization to form polycaprolactone, as shown in Figure 3.2.  It belongs to the group 
of polymers called aliphatic-polyesters, which typically possess hydrolytic instability, 
low melting temperatures, and solubility in common organic solvents, which ironically 
led to the belief in the mid 1900’s that these polymers were insufficient for use in 
practical applications, putting a halt on further studies.53  
 
Figure 3.2.  Ring opening polymerization of ε-Caprolactone to Polycaprolactone. 
 
Now, PCL is an FDA approved, biodegradable, non-toxic polymer that is used for a 
variety of biomedical applications.  It degrades much slower than other known 
biodegradable polymers through hydrolysis of its ester linkages in physiological 
conditions.51     Its byproducts, caproic acid and hydroxycaproic acid, are excreted by the 
body without complication.  In addition to being investigated as a scaffold material for 
tissue repair, has been used for drug delivery devices, suture, root canal filler and 
adhesion barrier. 
 
Aside from the conventional methods of porogen leaching and solvent casting, there are a 
number of SFF techniques that have been utilized to build PCL scaffolds including fused 
deposition modeling,4, 54-58  photopolymerization,59  precision extruding deposition,60, 61  
three dimensional printing,62  low temperature deposition,63  multi-nozzle freeform 
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deposition,64, 65  shape-deposition,66  selective laser sintering, 67-69  drop-on-demand 
printing,70  salt leaching and melt casting.  In Chapter 5, we use the SFF method of melt-
casting in order to create 3D-designed PCL scaffolds.   
 
When working with PCL, there is no option of varying aspects of “prepolymerization” 
(as we do with PGS, discussed later) in order to alter mechanical properties.  However, 
during the melt casting process used to fabricate scaffolds (see Figure 3.3), the molecular 
weight of the polymer used (see Table 3.2 for commercially available PCL) and the 
temperature at which the polymer is melted can be altered.  Aside from resultant changes 
in mechanical properties, the molecular weight of the polymer may also affect melt 
casting success. During fabrication, melt-casted PCL must be liquid enough to be cast 
into small wax mold pores to create thin scaffold struts.  However, lower molecular 
weight PCL, which will be more liquid, and hence easier to cast, may have inherently 
weaker mechanical properties.  In this thesis, we choose to examine the mechanical 
properties of the PCL products highlighted in Table 3.2.  Although all products could be 
used to successfully fabricate scaffolds, 14,000 Dalton PCL was quickly excluded from 

















CAPA 6100 10,000 white solid 
CAPA 6250 25,000 Pellets 
CAPA 6400 37,000 Pellets 
CAPA 6430 43,000 Pellets 
CAPA 6500 50,000 Pellets 




CAPA 6501  50,000 Powder 
CAPA 6503 50,000 Powder 
CAPA 6505 50,000 Powder 
CAPA 6806 80,000 Powder 
CAPA 6500C     
CAPA 6506 50,000 Powder 
Sigma 440752 14,000 Flakes 




Figure 3.3. Fabrication process for melt casted PCL scaffolds includes creating a green+red wax 
mold, melting off red wax and then pressing the green inverse mold into melted PCL.  The wax+PCL 
construct is then cooled before green wax is removed using 100% ethanol.   
 
Polycaprolactone has been used for a wide range of tissue engineering applications due to 
its slow degradative nature, relative inert biocompatible properties, and its mechanical 
strength.  Its extensive surge into tissue engineering applications include use for bone, 
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cartilage, smooth muscle, blood vessel, bladder grafting, and nerve tissue regeneration. 
This work will concentrate on its use for cartilage tissue repair. 
 
The degradation of PCL has been heavily documented and shown to be much slower than 
other degradable polymers.  Like other aliphatic-polyesters, PCL undergoes bulk 
hydrolysis characterized by a molecular weight loss up to 5000 due to chain scission, 
followed by the onset of weight loss.  Its slow degradation rates are attributed to its 
hydrophobicity and high crystallinity that do not allow fast water penetration.59   During 
its slow degradation, it does not generate an acidic environment and the byproducts that it 
does release (caproic acid and hydroxycaproic acid) can be naturally secreted by the 
body. In vitro (PBS, 37°C) PCL degradation has been characterized by weight loss of less 
than 2% after 42 days,59  no apparent changes in morphology, compressive mechanical 
properties, and weight loss up to 45 months,71  or no change in molecular weight (Mw) 
and molecular number (Mn) until at least 21 days, where-after Sung et al.72  show a 
significant decrease in molecular number (33% at day 21 and 39% at day 28).  However, 
Coombes et al.71  show no significant changes in Mn and Mw until 12 months.   PCL’s 
degradation in vivo is faster, with studies showing complete absorption in 60 days, in 
which phagocytosis of small particles is observed in the final stage,73  and more rapid 
changes in Mn, with a decrease of 42.6% at day 21.72  The slow in vitro degradation 
profile of PCL is advantageous for studies done in Chapter 7 of this thesis.  Because we 
look at how permeability affects chondrogenesis, it is essential to use a polymer that does 
not degrade throughout the in vitro culture time, thereby changing the permeability of the 
scaffold over time. 
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PCL has been shown to be compatible with a variety of cells types.  Osteoblasts,59, 67, 71  
smooth muscle cells,72  fibroblasts,55, 74, 75  bone marrow stromal cells,66, 76  and 
chondrocytes39, 77-79  are among the cells seeded onto PCL scaffolds for skeletal tissue 
engineering applications.  Focusing specifically on cartilage applications, studies have 
shown encouraging cellular infiltration, redifferentiation and proliferation of 
chondrocytes on PCL in vitro.78, 80-83   Eyrich et al.84  found that seeding cells into PCL 
scaffolds through encapsulating them in fibrin gel increased both the seeding efficiency 
and the homogenous matrix distribution.  Furthermore, both in vitro and in vivo studies 
have shown abundant proteoglycans and type II collagen expression on PCL scaffolds 
seeded with chondrocytes, embryonic stem cells, and bone marrow-derived mesenchymal 
stem cells (the latter of which were induced to differentiate down a chondrogenic lineage 
by culture in specific differentiation medias).30, 84-90   Oliveria et al.87  report better 
biocompatibility compared to PGA scaffolds where they see lack of tissue in the center of 
scaffolds possibly due to acidic byproducts.  PCL scaffolds have also been applied for 
use in osteochondral sites where studies show promising results in terms of bone growth, 
cartilage growth and integration.91, 92  In this work, we exploit the use of PCL for studies 
that involve seeding of chondrocytes and bone marrow stromal cells onto scaffolds with 
designed permeability.     
 
PCL is inherently hydrophobic, which can be a disadvantage for tissue engineering 
applications.  A number of studies have demonstrated the benefits of using surface 
modifications to overcome this hydrophobic nature.  Surface modifications of PCL 
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include use of acrylic acid, collagen, chitosan, NaOH, surface functionalization with 
NaOH, HCl, oxygen, or argon and coating with collagen 1 in order to improve cell 
adhesion, proliferation and function.93-96  
 
PCL’s array of fabrication possibilities lead to a wide range of mechanical properties for 
cartilage applications.  Examples of PCL particle leached sponges (0.607-8.15 MPa 
dependant on porosity),97  freeze-dried PCL (1.71 MPa),30  and 3D foams of Semi-IPN 
PCL-PVA crosslinked with 1% glutaraldehyde (1.52-3.51 MPa with increasing PVA 
concentrations correlating with increase in elastic modulus)86 have all shown properties 
within the ranges of native articular cartilage.  Elastomeric microporous poly(L-lactide-
co-epsilon-caprolactone) (PLCL)  sponges created by Xie et al.98  fall below these ranges 
(0.019 MPa), while another example of porogen leached sponges created by Izquierdo et 
al.77  fall above these ranges (6.85 ± 1.83 MPa).  All of these scaffolds, however, fall 
within the same magnitude of native cartilage properties, and are therefore promising for 
cartilage tissue engineering applications. 
 
In this research we use the SFF process of melt casting in order to produce designed 3D 
scaffolds for cartilage tissue engineering.  In Chapter 5, we demonstrate the importance 
of mechanically testing the material at 37°C for in vivo applications, quantify the 
contraction of melt cast PCL in ethanol (used during processing and sterilization), and 
characterize the effects that the processing parameters of melting temperature and 
polymer molecular may have on the equilibrium modulus of melt-cast PCL. 
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3.4  Poly(glycerol-sebacate) 
Unlike PCL, Poly(glycerol sebacate) (PGS) is just recently gaining popularity within the 
field of tissue engineering. Synthesis and characterization of the polymer, created through 
a polycondensation reaction of glycerol and sebacic acid (see Figure 3.4), was first 
reported in literature in 1999 by Nagata et al.99  In 2002, Wang et al.100  began using the 
polymer for biotechnology and bioengineering applications.  The group, out of MIT, 
created the polymer to provide good mechanical properties through covalent crosslinking 
and hydrogen bonding and rubberlike elasticity through a network of random coils with 
at least one trifunctional monomer.  They designed the polymer with established 
degradation and crosslinking mechanisms optimal for tissue engineering applications.  In 
order to satisfy tissue engineering requirements, they chose to use glycerol as the alcohol 
monomer and sebacic acid as the acid monomer.  Along with being tougher, inexpensive 
and more flexible than existing biodegradable elastomers, glycerol and polymers 
containing sebacic acid have been approved by the US Food and Drug Administration for 
medical applications.  To date, PGS has been used for applications in nerve guidance101 , 
soft tissue regeneration,102, 103  vascular and myocardial tissue regeneration,104-108  blood 
vessel reconstruction,109, 110  drug delivery,111  and in the replacement of photoreceptor 
cells.112  PGS is a biodegradable polymer with biocompatibility and mechanical 
properties that make it well suited for applications such as those mentioned above and, as 





Figure 3.4.  Polycondensation reaction of glycerol and sebacic acid to produce poly(glycerol sebacate) 
prepolymer. 
 
PGS is processed through creating a prepolymer, and then curing this prepolymer at high 
temperatures to obtain a thermoset elastomeric polymer. The prepolymer form of PGS is 
fabricated through a polycondensation reaction.  In 1997, Nagata et al.99  produced a 
rigid, totally crosslinked polymer using a glycerol: sebacic acid ratio of 2:3 (molar ratio = 
2:3).  Most all literature thereafter reports use of equimolar amounts of glycerol: sebacic 
acid (molar ratio = 1:1), which result in a less rigid polymer.  Liu et al. 113  also report a 
“two-step” method, in which they react the pre-polymer at a 1:1 molar ratio, and then 
continue adding sebacic acid until they reach a molar ratio of 2:2.5. This procedure 
creates a thermoplastic elastomer with increased strength and elongation and slower 
degradation than the previously reported thermoset PGS.  In this thesis, using the original 
synthesis method outlined by Wang et al,.100  we will characterize how various molar 
ratios of glycerol to sebacic acid (3:4, 1:1, 4:3) affect the elastic modulus of the material.   
 
After prepolymer synthesis, the polymer must be cured at high temperatures in order to 
create the final product.  During the curing process, micropores are created (~5-20um) 
through the removal of glycerol.103   Most studies to date cure PGS at 120°C, however, in 
2006 Gao et al.103  show that at 150°C the transesterification reaction is far more 
extensive than at 120°C, creating more micropores in the resultant polymer.  In 2008, 
Chen et al.106 characterize the changes in Young’s modulus, failure stress, and 
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degradation rate that result from a change in curing temperature (110°C v. 120°C v. 
130°C).  They report that the Young’s modulus of PGS increases from .56MPa at 110°C 
to 1.2MPa at 130°C and that higher curing temperature results in lower failure stress and 
slower degradation.  In this work, we use a consistent curing temperature of 150°C.   
 
Since 2002, a number of groups have been processing PGS for tissue engineering 
applications.  Most studies have fabricated the polymer through conventional methods, 
creating films or porogen-leached sponges.  Motlagh et al.109 and Crapo et al.110  
demonstrate curing the polymer into tubular sheets and films to create scaffolds for blood 
vessels, renal tubules, or various ducts.  In this thesis, we demonstrate the ability to 
fabricate PGS scaffolds through SFF techniques in order to create designed pore shapes, 
pore sizes, porosities, and architectures.  Fabrication of PGS by this means was not yet 
reported. Because PGS must be cured at temperatures greater than the melting 
temperature of ProtoBuild molds, an intermediate hydroxyapatite mold must be created 
and cast into the pPGS in order to create designed architectures.  Details of the 




Figure 3.5.  Fabrication of 3D designed PGS scaffolds involves first creating wax molds, which are 
cast into hydroxyapatite in order to create an inverse mold, which is then cast into PGS prepolymer 
and cured, resulting in a PGS scaffold.  
 
Since 2002, the biocompatibility of PGS has been reported for a variety of bioengineering 
applications.  In their original work, Wang et al. 100 demonstrate its biocompatibility with 
NIH 3T3 fibroblasts. They show that PGS induces little, if any, fibrous capsule formation 
and that it has an inflammatory response similar to that of PLGA when implanted in 
under the skin of rats.  Positive results have also been shown for attachment, 
proliferation, and viability of Schwann cells (as a nerve guide),101  human umbilical vein 
endothelial cells (for vascularizing TE organs),108  platelets (for blood vessel 
applications) 109 , and hepatocytes (for replacement of tissue and organs).114  The most 
frequent application of PGS to date has been in heart and vascular tissue.  Seeding of 
cardiac fibroblasts on PGS show favorable levels of contraction and excitation and form 
layers of elongated myocytes aligned in parallel over layers of fibroblasts.104  Endothelial 
progenitor cells, and smooth muscle cells adhere, proliferate and show favorable 
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phenotypic and morphological properties.105  And, in 2007, PGS began being used for 
drug delivery by Nijst et al.,111  as they demonstrated a way to mildly process the material 
allowing for encapsulation of temperature sensitive factors, and showed sufficient cell 
adhesion and proliferation of human foreskin fibroblasts.  In this work, we show the 
biocompatibility of PGS with chondrocytes for cartilage tissue engineering applications.  
 
One main advantages of using PGS for tissue engineering, exploited in this research, is 
that its mechanical properties can be tailored to match specific tissue properties simply 
through altering processing parameters during the prepolymer and/or curing steps. To 
date, most mechanical testing of PGS has been done in tension.  Tensile tests on pure 
PGS have shown that it can be elongated repeatedly to at least three times its original 
length, with a tensile Young’s modulus of 0.282 ± 0.0250MPa and an ultimate strength 
>0.5 MPa.100   Using the two-step processing method, Liu et al.113  demonstrate slightly 
higher elastic modulus values (.45-.55MPa), but lower tensile strain (109-236%).  Using 
milder processing conditions for drug delivery applications, Nijst et al.111 report values 
for Young’s modulus of .05-1.38MPa, ultimate strength values of .05-.5MPa, and 
elongations of 42%-189%. And, in 2008, Chen et al.106  demonstrate the ability to alter 
the mechanical properties of PGS by variation in curing temperatures, recording Young’s 
modulus values of .056 MPa (110°C), .22MPa (120°C), and 1.2MPa (130°C), with their 
results for 120°C closely matching those of Wang’s results for the same conditions.  
Compression testing done on salt leached PGS foams have resulted in lower moduli that 
range from ~4.5 kPa to ~7 kPa,103  dependent on both the PGS/salt ratios and the size of 
the salt particles used. And, although Wang et al.102  tested sheets of solid PGS in 
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compression to assess the materials degradation, they fail to report raw values for their 
compressive modulus results.  Here, we test solid PGS cylinders and novel 3D-designed 
scaffolds in compression to determine the non-linear elastic properties of this material.   
 
Although we will not examine the degradation of PGS in this work, it is important to note 
its degradative properties.  PGS degrades much more quickly than does PCL.  In vitro, 
the material loses 17% of its mass after 60 days.100   The degradation of PGS in vivo has 
been shown to be much quicker than in vitro, likely due to the esterases associated with 
macrophages shown to degrade polyesters.111   As a direct comparison, after 60 days in 
vivo, the material is totally absorbed.   In vivo, PGS undergoes surface erosion, resulting 
in a number of benefits for tissue engineering applications including a linear degradation 
profile of mass, preservation of geometry, and retention of mechanical strength.  There 
are a number of factors that contribute to changes in degradation.  Liu et al.115 report that 
thermoplastic-PGS (TMPGS) degrades more slowly than PGS, and show that the 
prepolymer molecular weight affects degradation speed, but not mechanism.  Lowering 
of the curing temperature causes PGS to degrade more quickly (in PBS)106  as does cell 
seeding onto the material.107  And, although not studied here, it is likely that the 
degradation profile of PGS could also be altered through variations in prepolymer molar 
ratios or curing time.  
 
An additional benefit of PGS in tissue engineering applications is its lack of swelling in 
water.  When cured at 120°C, Wang et al.100  and Chen et al.106  show low swelling 
values, 2% and 4% respectively.  Chen et al.106  also report that swelling is decreased 
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with increasing curing temperature (2.5% at 130°C).  Solid cylinders used for our studies, 
cured at 150°C, showed no significant swelling. 
 
Here, we use this novel material to create 3D designed scaffolds for cartilage tissue 
engineering applications.  Although the material exhibits a purely elastic response, in 
comparison to the viscoelastic response of native cartilage, matching this to cartilage 
equilibrium modulus is a good first step, as there is no data that indicates how critical it is 
to match all cartilage properties exactly to achieve adequate function and superior tissue 
regeneration.  We show that the elastic modulus of PGS can be tailored through 
variations in prepolymer molar ratios and changes in curing time.  With an established 
database of mechanical properties for different processing parameters, we can match the 
mechanical properties of a wide range of scaffold architectures to the properties of native 
tissue.   As proof of concept, we show that chondrocytes can be seeded into the scaffolds, 
and cultured in vitro to produce quantities of sGAG and expression of cartilage specific 
markers comparable to or higher than values produced on relatively inert PCL.   
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CHAPTER 4 
DESIGNED SCAFFOLD PERMEABILITY FOR CARTILAGE 
REGENERATION 
 
In designing 3D cartilage scaffolds, the hope would be that there is an optimum window 
of structural feature sizes that both mimic the mechanical properties of articular cartilage 
and allow for optimal tissue in growth.  Some groups state their hypothesis that providing 
maximum porosity will promote tissue in growth.1   Though this may be true for bone 
tissue engineering, it must be understood that for cartilage tissue engineering this increase 
in porosity correlates with an increase in permeability, contradicting a number of 
findings. Clinically, healthy cartilage has relatively low permeability, and increases in 
permeability are correlated with disease and deterioration.  Basic science has shown that 
decreases in permeability with tissue depth correlates with a rise in proteoglycan 
content.2   And in tissue engineering studies, cartilage grows in anaerobic conditions 
where oxygen diffusion is low.3-5    
 
Many groups have measured the permeability of bovine cartilage in order to characterize 
the tissue or quantify changes due to diseases or injuries.6-13    Compared to the 
permeability of hard tissues, such as cancellous bone (.002 – 2 x 10-8 m4/Ns) or 
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cortical bone (.79 – 9 x 10-12 m4/Ns), soft tissues including intervertebral disc (1.2-1.9 x 
10-15 m4/Ns), meniscus (0.6 x 10-15 m4/Ns), ligament (1-6 x 10-16 m4/Ns), and articular 
cartilage (0.1 – 2.0 x 10-15 m4/Ns) exhibit relatively low permeability.14   In reference to 
disease and damage, an increase in permeability of articular cartilage results in greater 
and more rapid deformation of tissue.15, 16   Alexopoulos et al.17 developed a finite 
element model to show that lower permeability in the pericellular matrix of healthy 
cartilage reduces local fluid fluxes that are increased in osteoarthritic tissue.  They 
suggest that chondrocytes are sensitive to these changes in the pericellular matrix.  
Changes in fluid movement, as governed by tissue permeability, affect nutrient transport, 
hydrodynamic lubrication, mechanical signaling, and cellular level shear stresses.  This 
finding is not only important for clinicians studying disease state, but is also relevant to 
the design of tissue engineering scaffolds. 
 
4.1  TISSUE ENGINEERING AND PERMEABILITY 
Reproducible fabrication of specific scaffold designs through SFF enables us to study 
how structural features can influence cartilage regeneration.  Most studies to date have 
examined the effects that pore size, pore shape, or interconnectivity have on tissue 
production by chondrocytes in vitro.  Some studies show that a larger pore size, higher 
porosity, or increased connectivity (all presumably related to increased permeability) 
support better migration and higher proliferation of cells, greater amounts of GAG-
deposition, and increased collagen II content.18-20  One study that reports improved 
chondrocyte proliferation, higher metabolic activity and more overall GAG with 
increasing pore size, also shows that when this increased GAG is normalized to DNA 
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content, there is no significant difference, suggesting that the increased GAG content per 
construct is most likely just due to increased cellularity.18   Another study reports that 
although increased pore size results in higher GAG/DNA content on a more hydrophilic 
polymer composition, this is not seen in more hydrophobic scaffolds.19   Additionally, 
Malda et al.21  show no effect of pore size on GAG content in vitro, but demonstrate that 
in vivo an increased pore size produces greater amounts of GAG. The studied effects of 
these structural properties on chondrogenically-pulsed mesenchymal stem cells seeded 
into nonwoven fibrous meshes, shows that an increase in porosity and pore size (resulting 
in a measured increase in gas permeability) supports more rapid proliferation, and greater 
synthesis and retention of GAG.22  
 
In contrast, there is evidence showing that structural properties that would presumably 
decrease permeability show more favorable results for chondrogenesis.  Beginning in 
1973, Reddi and Huggins show that closed tubes (versus open tubes) favor 
chondrogenesis over osteogenesis, concluding that higher oxygen and nutrient supply 
favor the latter.23   Yoon et al.24  show that chondrocytes seeded in denser alginate gels 
produce more collagen II and IGF-1 mRNA expression.  They hypothesize that this could 
be due to an increase in the diffusional resistance of soluble molecules.  Pore size effects 
on chondrogenesis show that a smaller pore size is most favorable, with one study 
showing increases in the percentage of cells that remain spherical in shape and increases 
in GAG/DNA on a 20µm pore size.25   And, although another study shows that their 
smallest pore size of 13µm produces a thicker layer of cartilage and greater amounts of 
GAG, the sGAG content per DNA is not different, nor was the amount of collagen 
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accumulated per cell.4   Finally, Kuboki et al. suggested that smaller pores are more 
favorable for chondrogenesis when they saw endochondral ossification on 90-120 µm 
pores and direct bone formation on 350 µm pores.26    
 
Taken together, these studies demonstrate that there is no consensus on how the structural 
properties of pore size, porosity, and interconnectivity affect chondrogenesis.  Li et al., 
however, prove that none of these properties (also including pore distribution, 
fenestration size and distribution, and orientation of pores) can be used individually to 
describe mass transport.  Instead, they suggest that “one conventional physical 
parameter”, permeability, be used as a description of the complicated porous structures 
encountered in the process of tissue engineering.27  In this work, we examine how the 
physical property of permeability, as described by Darcy’s law, affects chondrocytes or 
bone marrow stromal cells seeded onto PCL scaffolds and cultured in vitro, with the 
hypothesis that this parameter can be used to more accurately predict the effects of 
scaffold architecture on chondrogenesis.   
 
4.2 ONE EXPLANATION: OXYGEN TENSION 
One explanation for the effects that scaffold permeability has on cartilage tissue 
regeneration is described by its correlation with oxygen tension.   In native tissue, oxygen 
tensions follow the same trend as permeability, where embryonic cartilage exhibits low 
oxygen levels (5-10%) 5, 28, 29  in contrast to bone (~25%).30   In normal conditions, 
chondrocytes are living in an environment with low oxygen supply.  And, it is proposed 
that increases in oxygen levels (hyperoxia) may result in the disturbance of chondrocytic 
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metabolism.  In their review on the effects of oxygen tension on cartilage tissue, Malda et 
al.5  conclude that “low oxygen induces production of cartilage specific components and 
structure of the extracellular matrix, whereas hyperoxia disturbs chondrocyte metabolism 
and inhibits production of proteoglycans.” This statement, however, is surrounded by 
much scientific controversy.   
 
In response to variations in partial oxygen pressure chondrocytes produce abnormal 
levels of reactive oxygen species (ROS), including nitric oxide (NO) and superoxide 
anion (02-). These ROS, and the derivative radicals that they generate, have effects on 
intracellular signaling, chondrocyte apoptosis, and matrix synthesis and breakdown.  In 
normal cartilage ROS are produced at low levels in response to a low oxygen 
environment, where they are positively involved in the control of cellular functions.  
Equilibrium between ROS production and intracellular antioxidants is modulated, in part, 
by oxygen tension in the tissue.  In joint diseases, such as osteoarthritis and rheumatoid 
arthritis, ROS are produced in greater amounts, resulting in oxidative stresses that cause 
degradation of cellular membranes, nucleic acids, proteoglycans and collagens, resulting 
in deterioration of the tissue.31  
 
Herontin et al.31  explain that the exposure of chondrocytes to H2O2 (a ROS derivative) 
inhibits proteoglycan and DNA synthesis.  However, there is evidence of both inhibitory 
and stimulatory oxygen effects on chondrocyte maintenance or redifferentiation of 
chondrocytes in monolayer and 3D in vitro environments.  Oxygen tensions in these 
studies are imposed through variations in overall oxygen supply to the in vitro 
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environment, from .1%, 1% or 5% (low oxygen conditions, similar to that of healthy 
cartilage) to 20 or 21% (high oxygen conditions). 
 
De-differentiated chondrocytes favor low oxygen supply for redifferentiation in 3D 
culture, where studies show increased proteoglycan synthesis, upregulation of collagen 2 
and aggrecan, and down-regulation of collagen 1.32-35   However, these effects are not 
seen with the same cells cultured in monolayer. 33, 35  There are conflicting effects of 
oxygen tensions on differentiated chondrocytes in 3D and monolayer culture.  Most 
studies support the hypothesis that decreased oxygen levels mimic natural cartilage, 
showing increases in collagen 2, better shape, cellular distribution, tissue smoothness, 
proteoglycan content, and decreased collagen 1 expression.36-41  However, there are a 
couple of studies that contradict these findings, showing decreases in collagen 2 and 
matrix production at low oxygen levels, and increases in GAG in response to high 
oxygen levels.42-45   Also of note are studies that show no chondrogenic differences in 
response to changes in oxygen tension, suggesting that these cells are insensitive to these 
variations.46, 47  In support of our hypothesis that lower permeability will enhance matrix 
production by chondrocytes, Malda et al.5  state that “low oxygen conditions in vitro 
mimic the in vivo cartilage environment, and are thus likely to be a specific stimulus, 
decreasing dedifferentiation during expansion and enhancing redifferentiation of 
chondrocytes in vitro.”   
 
A number of studies have also looked at the effects of imposed oxygen tensions on 
differentiation of BMSCs down a chondrogenic lineage.  Kanichai et al.48  report 
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increased collagen 2 and proteoglycan deposition in response to low oxygen tension. 
Robins et al.49  support this finding in 3D, reporting an increase in sox 9, collagen 2, and 
aggrecan, and furthermore, revealing that these upregulations are accompanied by an 
increase in nuclear accumulation of a hypoxia-inducible factor (HIF-1α). 
 
Oxygen tension in 3D-designed scaffolds is inherently varied through designed changes 
in permeability.  However, nobody has studied the effects of controlled scaffold 
permeability on chondrogenesis by chondrocytes or bone marrow stromal cells as seen in 
Chapter 7. In Chapter 7, differences in matrix production and cartilage-specific gene 
expression by chondrocytes and BMSCs, seen in relation to changes in permeability, may 
be explained in part by correlating variations in oxygen tension caused by the designed 
changes in permeability of these scaffolds.     
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CHAPTER 5 
CHARACTERIZATION OF 3D-DESIGNED MELT CAST POLY(ε-
CAPROLACTONE) SCAFFOLDS FOR CARTILAGE TISSUE ENGINEERING 
 
 
5.1 Introduction  
Polycaprolactone (PCL), an FDA approved, biodegradable, nontoxic polymer has gained 
popularity in the field of tissue engineering over the past decade.  PCL’s slow 
degradation profile coupled with its strong mechanical properties make it ideal for 
applications in bone and drug delivery, where it has commonly been applied.  Recently, 
this material is being used in a wider range of applications, including osteochondral 
repair, spinal cord regeneration, bone, cartilage, smooth muscle, blood vessel, and 
bladder grafting.  Here, we concentrate on its applications for cartilage tissue 
engineering. 
 
Commercially available PCL is being fabricated in a variety of ways for tissue 
engineering applications.  Methods include fused deposition modeling,1-6  
photopolymerization,7  precision extruding deposition,8, 9 three dimensional printing,10  
low temperature deposition,11 multi-nozzle freeform deposition,12, 13 shape-deposition,14  
selective laser sintering,15-17  drop-on-demand printing,18  salt leaching and melt casting. 
Each fabrication process has unique advantages and disadvantages, along with unique 
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material properties that are often reported as being solely dependent on scaffold design 
(pore size, porosity, fiber size) for each fabrication method.   
 
When applying any of the aforementioned fabrication it is desirable to create scaffolds 
that have mechanical properties similar to the tissue being regenerated.  Here we focus on 
matching the equilibrium aggregate modulus (HA) of a scaffold to that of native articular 
cartilage.  By matching target HA values of articular cartilage, the scaffold will withstand 
physiological loading, produce the mechanical tension generated within the cell 
cytoskeleton critical for cell shape and function, and mimic stiffness values that may 
affect cell to cell contacts and aggregation.19   Furthermore, when the scaffold (with or 
without tissue) is implanted into a defect site, there should ideally be no stiffness 
differences between healthy cartilage and regenerating tissue.  Differences in tissue 
mechanical properties may cause fibrous tissue formation, elevated levels of strain in the 
adjacent cartilage, and acceleration of degeneration of the tissue.20   There are two 
components that determine the final effective scaffold stiffness: 1) the base material 
stiffness and 2) the scaffold pore architecture.  Since pore geometry may be restricted by 
tissue in growth requirements, it would be advantageous to also alter effective scaffold 
stiffness by altering the base material stiffness.  With a specific focus on the fabrication 
method of melt casting, here we characterize how the processing parameters of molecular 
weight and melt-casting temperature may be used to alter the HA of PCL scaffolds for 
cartilage applications.  We also demonstrate the importance of mechanically testing PCL 




Integration of image-based design and analysis (IBEA) techniques{{318 Hollister,S.J. 
2000; 301 Hollister,S.J. 2005}} with solid freeform fabrication (SFF) of scaffolds is 
advantageous as an engineering choice that can exploit the control and variability of 
mechanical properties of synthetic polymers.  When matching mechanical properties of 
scaffolds to native tissue properties, IBEA-SFF grants us the ability to accurately 
determine mechanical properties of scaffold designs through finite element analysis 
(FEA), simply by knowing the bulk material properties polymers that can be used for 
scaffold fabrication.  Here we show that we can use the aggregate modulus values of 
solid PCL cylinders in order to accurately predict that aggregate modulus values of 
various scaffold designs from the computational design phase through the actual 
fabricated scaffold.  
 
It is also important to fully characterize 3D designed scaffolds in terms of their structural 
properties before carrying these fabrication processes into clinical applications.  Here we 
characterize the contraction of melt-cast PCL caused by post-processing of the scaffolds 
in ethanol.  When designing custom scaffolds modeled from MRI or CT images of 
specific patient defects, it is important to compensate for any change un structural 
dimensions that may be altered during processing, such as swelling or contraction of the 
material.  
 
The importance of fully and accurately characterizing the mechanical and structural 
properties of 3D designed scaffolds, and determining means by which these properties 
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can be altered for specific clinical applications is evident.  Here we show that the 
aggregate modulus values of melt-cast PCL scaffolds are not significantly altered through 
changes in molecular weight (within the ranges of 25 kDa to 50 kDa) or melt-casting 
temperature (with the ranges of 110°C to 150°C).  However, in carrying out these 
experiments, we demonstrate the importance of performing these mechanical tests at 
physiological temperatures, characterize the contraction of this material in ethanol, and 
provide support for the use of FEA programs in order to non-destructively predict the 
mechanical properties of SFF scaffolds.   
 
5.2  Materials and Methods 
Fabrication of solid PCL cylinders  
Solid PCL cylinders (approximately 3 mm height, 6.35mm diameter, n=15 per group, 
total = 180 cylinders) were made by placing PCL pellets (25, 37, 43 kDa) (Solvay 
Caprolactones, Warrington, Cheshire, UK, product #s 6250, 6400, 6430),  or PCL 
powder (50kDa) (Polysciences Inc., Warrington, PA. CAT# 19561) into a Teflon mold 
which was then melted (110°C, 130°C,  or 150°C, 1 Torr, 5 hours).  Preliminary work 
done melting PCL at 90°C showed that at this lower temperature, the PCL did not fully 
settle, and as shown through µCT imaging, air bubbles were present throughout the 
cylinder.  This group was therefore excluded from further study.  After melting, the 
Teflon mold was removed from the oven and allowed to cool at room temperature for 24 
hours.  For accurate mechanical testing, two parallel surfaces were created using a 
Polycut machine (Leica, Inc., Deerfield, IL).  Cylinders were then soaked in 70% EtOH 
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for 24 hours followed by soaking in phosphate buffered saline (ph 7.4, GIBCO) for 12 
hours prior to mechanical testing. 
 
A second series of solid PCL cylinders were fabricated with the same polymer molecular 
weight and melting parameters as scaffold fabrication (37kDa, 115°C, 1 Torr, 120 
minutes).  The bulk mechanical properties from these cylinders were used for finite 
element analysis calculations described below. 
 
Fabrication of 3D Designed Scaffolds 
Three-dimensional (3D)-designed scaffolds (3mm height, 6.85mm diameter, 1mm 
spherical pores) were designed using custom Interactive Data Language™ programs 
(IDL; Research Systems, Inc., Boulder, CO).  Scaffolds were designed with 100% 
interconnected, 1mm, spherical pores with variations in throat size between pores that 
resulted in three design porosities (54%, 63%, 70%)  Inverse wax molds of the designs 
were built on a Solidscape MM2 3D printer (SolidScape Inc., Merrimack, NH). Scaffolds 
were made by pressing inverse wax molds directly into melted 37kDa polycaprolactone 
(CAPA 6400, Solvay Caprolactones, Warrington, Cheshire, UK).  Briefly, PCL pellets 
were placed into a Teflon mold, and melted (115°C, 1 Torr, 120 minutes). After melting 
and air bubble removal, the Teflon mold was pulled from the oven, and allowed to cool 
for 270 seconds at room temperature until it reached 80°C (just below the melting 
temperature of the wax molds).  At this time, inverse wax molds were pressed into the 
melted PCL, and the entire construct was cooled overnight.  The wax was then dissolved 
from the PCL using 100% EtOH.  A schematic of this process was shown in Figure 3.3. 
 71
Scaffolds were designed for future studies on the effects of permeability on tissue 
regeneration, and are therefore referred to as a “low, mid and high” permeability designs. 
 
Although it is necessary to heat PCL to higher temperatures in order to eliminate air 
bubbles, by allowing melted PCL to cool to 80°C before casting the wax mold into the 
material, we eliminate the need for production of a secondary hydroxyapatite scaffold 
previously used to manufacture these scaffolds in our lab. 22  
 
Mechanical Testing of Solid cylinders and 3D designed scaffolds 
Stress relaxation testing was performed in confined compression using an MTS Alliance 
RT30 electromechanical test frame (MTS Systems Corp., MN), following a protocol 
established by Guilak et al.23 and used extensively in the field by others.24, 25  Following a 
preload (0.67 N (solid cylinders) or .22 N (scaffolds), 600s hold) the crosshead was 
lowered to 10% strain at .25µm/s, and then held at constant displacement for 30 minutes. 
Cylinders were tested at 37°C, in PBS and scaffolds were tested at both 37°C, in PBS and 
room temperature in PBS.   
 
The stress relaxation behavior was characterized using a quasi-linear viscoelastic model.  
The nonlinear elastic portion was modeled using a 1D model commonly used in 
biomechanics: 
 
( )1BT A e ε= −
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Where T is the 1st Piola-Kirchoff stress used for large deformation, e is the large strain, 
and A, B are model constants fit to experimental data.  The reduced relaxation function 
was approximated using a three term Prony series of the form: 
 
( ) 1 20 1 2
t t





Where G represents the reduced relaxation function, t is time, and c0, c1, c2, τ1, and τ2 are 
model constants fit to experimental data.  The model constants c0, c1, and c2 are further 
required to satisfy the constraint: 
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Using the reduced relaxation function and elastic response stress as a function of time is 
calculated as: 
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τ  is the strain rate and the other parameters are as defined previously.  The 
stress T(t) can be calculated for the ramp strain test.  The model constants A, B c0, c1, c2, 






utilizes the nonlinear programming algorithm fmincon.  The aggregate modulus (HA) is 
computed as the stress divided by strain at the end of the ramp.  
 
Finite element analysis on scaffold designs 
Complete anisotropic effective stiffness constants were calculated using the voxel-based 
homogenization software VOXELCON (Quint Corp, Tokyo, Japan), as described 
previously.15  Briefly, voxel models were created of both the design input STL files of 
scaffold designs and the voxelized µCT scans of actual fabricated scaffolds for each 
design.  STL files were first converted to .vox files, and then .jpeg files. Microview was 
used to select a repeating periodic region of interest (ROI) within the STL file, and the 
ROI was exported in .png format, and then converted to a .raw image.  This .raw image 
was imported into VOXELCON for finite element analysis.  The µCT scanned scaffold 
images were imported into Microview and a ROI was selected from the center point of 
the scaffold.  This ROI was exported in .png format and the same sequence of routines 
was performed as were on the STL files.  For the finite element analysis, PCL aggregate 
modulus values from mechanical testing results of solid cylinders were converted to 
elastic modulus values using the equation described by:    
  
 
Where E = elastic modulus, ν = Poisson’s ratio. These elastic modulus values were input 
into VOXELCON, with a Poisson’s ratio of 0.2, and run on scaffold designs.  
VOXELCON output an effective elastic modulus and effective Poisson’s ratio for each 
design that was then input back into the equation to determine the effective aggregate 
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modulus (HA) of each scaffold design for each molecular weight and curing temperature 
tested.  
 
Measuring Contraction of PCL 
Contraction of melt-cast PCL was measured for solid PCL cylinders and 3D-designed 
scaffolds.  Cylinders and scaffolds were scanned dry using a MS-130 high resolution 
micro-computed tomography (µCT) scanner (GE Medical Systems, Toronto, CAN) at 16 
µm voxel resolution, 75kV and 75mA.  GEMS Microview software was used to analyze 
µCT data.  3D designed scaffolds (n=5) were scanned at three phases throughout 
processing: after the wax mold had been cast into PCL material and after removal of wax 
mold during a 30h EtOH soak.  Changes in outer diameter and overall porosity are 
reported.  
 
In Vitro Experiment 
As proof that these scaffolds can be used for cartilage regeneration, scaffolds (n=4 for 
each of 3 designs) were seeded with fresh porcine chondrocytes, harvested from 
metacarpophalangeal joints of domestic pigs (Northwest Market, Northwest, MI).  3.2 x 
106 chondrocytes were suspended in 50µl of type 1 rat tail collagen (stock concentration: 
5.9 mg/ml, BD Biosciences, # 354236) and subsequently seeded into each PCL scaffold 
(cell density = 64 x 106 cells/ml). The collagen was gelled for 30 minutes at 37°C before 
scaffolds were removed from the custom Teflon seeding mold, and placed into wells of 
media (DMEM, 10%FBS, 1% P/S, 0.1mM Non-essential Amino Acids, 50 µg/ml 2-
phospho-L-ascorbic acid, 0.4 mM proline, 5ug/ml insulin). Scaffold+collagen gel+cells 
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were grown in vitro (37°C, 5% CO2) on an orbital shaker.  After 2 weeks, scaffolds were 
removed, fixed in zinc formaldehyde (ZFIX, Anatech, Battle Creek, MI) overnight, 
dehydrated in EtOH washes, and paraffin embedded. Sections were stained with 
Safranin-O (with a Fast green counter stain) to illustrate GAG production. 
 
Statistical Analysis 
Statistical analysis, including 2-way ANOVA and student t-tests, were performed in 
SPSS software (SPSS for Windows, Rel 14.0. 2005 Chicago: SPSS Inc.).  
 
5.3. Results 
Mechanical Variations due to Melting Temperature and Molecular Weight 
PCL solid cylinders and 3D-designed scaffolds both exhibited stress-relaxation profiles, 
as seen in Figure 5.1. In the ranges used for this study, variations in melting temperature 
(110°C - 150°C) and molecular weight (25kDa-50kDa) show no significant trends for 
altering the equilibrium aggregate modulus of bulk PCL (two-way ANOVA) (Table 5.1 
and Figure 5.2).  There were also no significant differences within melt temperature 
groups with regards to changes in molecular weight, or within molecular weight groups 






















































Figure 5.1. Solid PCL cylinders and 3D-designed PCL scaffolds both exhibit stress-relaxation profiles. 
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Table 5.1.  Equilibrium aggregate modulus of solid melt-cast PCL (25, 37, 43 or 50 kDa)cylinders processed at 

















































Figure 5.2. Variations in processing parameters (molecular weight or melting temperature) of melt-cast PCL 
show no significant trends for altering the aggregate modulus of the bulk material.  
 
Mechanical variations between room temperature and 37°C testing 
Significant increases in aggregate modulus (One way ANOVA, linear regression) are 
seen when scaffolds are tested in stress relaxation at room temperature (21°C) versus 
Aggregate Modulus (MPa) 
Melt Temperature (°C) Solid Cylinder (n=7, n=6*) 
110 39.06 ± 12.83 43.99 ± 6.55* 39.05 ± 9.96 41.82 ± 6.18 
130 42.78 ± 10.45 28.75 ± 7.45* 33.28 ± 8.34 33.56 ± 8.38* 
150 41.99 ± 13.41* 32.78 ± 10.66 27.42 ± 7.11 32.39 ±  6.70 
 25 37 43 50 
 PCL Molecular Weight (kDa) 
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testing done at a physiological temperature of 37°C (Figure 5.3). Changes in testing 
temperature from 21°C to 37°C cause a 3.1 MPa increase in aggregate modulus (0.2 MPa 
/ °C) across all groups (R2 = 0.91, p ≤ 0.01).  This demonstrates the importance of testing 









































Figure 5.3.  Stress-relaxation testing performed at room temperature causes significant increases in 
the aggregate modulus of PCL scaffolds (0.2 MPa/°C). 
 
Contraction of PCL Scaffolds 
Processing in ethanol (EtOH) causes PCL scaffolds to contract significantly. Figure 5.4 
illustrates representative uCT images of a scaffold before and after EtOH soaking.  
Changes in scaffold outer diameter can be seen in Table 5.2.  Interestingly, there was no 
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Figure 5.4.  Contraction of PCL scaffolds after washing in 100% ethanol as measured by µCT.  
 









Finite Element Analysis to predict aggregate modulus 
FEA was used to calculate aggregate modulus values of scaffold design files and µCT 
images of actual scaffolds using a bulk material HA determined through stress-relaxation 
tests performed on solid cylinders of PCL (17.21 MPa) Table 5.2 displays computational 
and experimental HA values of the three PCL scaffolds used .  Aggregate moduli 
computed by FEA on design files and on uCT images correlated well with the 
experimentally measured moduli (R2 = 0.9764  , R2 = 0.9811, respectively) (Figure 5.5).  
Image-based FEA models created directly from µCT scans matched experimental moduli 
values more closely, as these images accounted for the contraction of PCL, which 









diameter    
(%) 
Low 6.782 ± .03 .422 ± .05 6.222 ± .70 
Mid 6.754 ± .06 .466 ± .08 6.910 ± 1.16 
High 6.722 ± .07 .404 ± .05 6.01 ± .77 
 Overall 
 6.753 ± .06 .431 ± .06 6.38 ± .96 
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resulted in increased volume fraction.  This verifies the ability of image-based FEA to 
compute scaffold stiffness without the need for destructive testing.  Testing the actual 
PCL scaffolds both experimentally and computationally validates the computationally 
predicted aggregate modulus data relative to the experimentally determined compressive 
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Figure 5.5. Correlations between experimentally measured aggregate modulus values and computational FEA 
predictions of design files (R2 = 0.9764) and µCT images (R2 = .9811) show that stiffness of scaffolds can be 
predicted without the use of destructive mechanical testing. 
 
In Vitro Experiment 
A histological image seen in Figure 5.6 confirms the presence of  sGAG and other 
cartilage proteins after 2 weeks in vitro culture of scaffolds seeded with chondrocytes 
embedded in a collagen I hydrogel. Safranin O staining is present throughout the scaffold 






Figure 5.6. Chondrocytes seeded within collagen 1 hydrogel produce cartilaginous matrix on 3D designed, melt 
cast PCL scaffolds after 2 weeks in vitro. 
 
 
5.4  Discussion and Conclusion  
Synthetic materials offer increased control and variation over scaffold mechanical 
properties.  Solid freeform fabrication (SFF) of scaffolds is an ideal fabrication choice 
that can exploit this control and variability.  In terms of matching mechanical properties 
of scaffolds to native tissue properties, SFF grants the ability to accurately determine 
mechanical properties of scaffold designs through finite element analysis, simply by 
knowing the bulk material properties of the polymers that can be used for scaffold 
fabrication.  SFF also provides many benefits specific to cartilage tissue engineering.  On 
a global scale, it enables design and fabrication of anatomically shaped scaffolds.  For 
osteochondral applications, it allows creation of biphasic scaffolds that incorporate 
multiple geometries into a single scaffold 26, 27  allowing for in-growth of multiple tissues 
into a single structure.  Particularly beneficial for articular cartilage applications, it allows 
creation of zones of organization within a single tissue compartment.28   Native cartilage 
exhibits a superficial zone (elongated and flattened chondrocytes arranged in fascicles 
parallel to the surface), an intermediate zone (round chondrocytes randomly distributed), 
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and a deep zone (chondrocytes arranged in short columns)29   SFF allows the 
incorporation of distinctly designed architectural zones into a single scaffold, allowing 
recapitulation of this native organizational scheme. More locally, SFF allows for precise 
control of internal architectures, such as pore size, pore shape, interconnectivity and 
porosity.  This increased control, over conventional methods, creates excellent 
reproducibility of intricate architectures, providing obvious benefits to basic science 
research and clinical applications.  Within the field of tissue engineering research, it 
enables us to study how various scaffold architectures may affect cell infiltration, mass 
transport of nutrients and metabolic waste, and thereby influence tissue regeneration.  
Several authors have reviewed the advantages of SFF techniques currently in use for a 
wide array of applications. 1, 13, 30-40  
 
The repair strategy that this work aims to achieve using SFF is described by Hutmacher 
et al. as “strategy 1” in which “the physical scaffold structure supports the 
polymer/cell/tissue construct from the time of cell seeding up to the point where the 
tissue transplant is remodeled by the host tissue.”1  Although scaffold mechanical 
properties can be changed by altering porosities and pore sizes, these changes also affect 
tissue regeneration in complicated manners.  The ability to match initial properties 
through changes in bulk material properties is an advantageous route to pursue.   
 
Studies have demonstrated that, due to influences on setting behavior, both molecular 
weight and preparation temperatures have an effect on polymer mechanical properties.  A 
study on poly(acrylic acid) shows that compressive and tensile mechanical properties are 
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increased with increasing additive molecular weight.41  Nicholson et al. 42 show that the 
elastic properties, inelastic elongation behavior, and tensile strength of an advanced 
polymer (LaRC™-SI) are affected by processing temperature and molecular weight, 
where Young’s modulus and tensile strength decrease with increasing temperatures, and 
tensile strength increases with increasing molecular weight.   The ability to predict and 
vary the performance of PCL scaffolds based on intrinsic material properties is highly 
desirable.  Unfortunately, aggregate modulus values of solid PCL cylinders are not 
significantly altered when the processing parameters of molecular weight and melting 
temperature are varied.  Although even higher molecular weight PCL could be explored, 
for melt casting it is likely too viscous at 80°C to be successfully cast.    
 
Accurate assessment of melt-cast PCL scaffolds is necessary in order to ensure that the 
scaffold properties are within the range of articular cartilage. Although it seems natural to 
mechanically test scaffolds for in vivo applications at physiological temperatures, it is not 
always done, probably due to the more intricate set-up involved.   This work shows the 
importance of mechanically testing PCL at physiological temperatures for medical 
applications where the material will be implanted.  An increase from 21°C to 37°C cause 
a significant change (3.1 MPa) in aggregate modulus  that should not be overlooked.  
 
Finite element analysis can be used to accurately predict the aggregate modulus of 
scaffolds based on known bulk material properties of melted PCL.  When designing more 
intricate architectures or creating custom implants, prediction of scaffold properties 
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(whether on a design file or on a µCT image) through FEA will allow non-destructive 
mechanical analysis of a specific construct.   
 
Ethanol is often used for processing of scaffolds, as shown here to dissolve wax, or in 
many instances to sterilize implants. Here, we find that EtOH causes significant 
contraction of 37 kDa PCL, due to molecular compaction of the carbon chain or a change 
in bond structure when placed in a polar solution. In separate work, it was found that 
50kDa powder PCL exhibited the same contraction profile.  When designing custom 
scaffolds it will be important to compensate for contraction of material seen in this study.  
Computational up scaling of the scaffold implant could be applied to fix this change, or a 
less polar solvent, that does not cause contraction, can be investigated for removal of wax 
(note: acetone was also investigated, but caused warping and deterioration of the PCL 
scaffolds before wax was dissolved out). Compensating for the contraction of PCL is also 
important in situations where the material will be placed in a polar in vivo environment. 
For instance, Yu et al.43  document contraction of PCL in bladder applications, where the 
material is in contact with urine.  
 
PCL has been shown to be compatible with a variety of cells types.  Osteoblasts,7, 44  
smooth muscle cells,45  fibroblasts,3, 46, 47  bone marrow stromal cells,14, 48  HGFs,15 and 
chondrocytes49-51  are among the cells that have been seeded onto PCL scaffolds for 
skeletal tissue engineering applications.  Focusing specifically on cartilage applications, 
studies have shown encouraging cellular infiltration, redifferentiation, and proliferation 
of chondrocytes on PCL in vitro.50, 52-55  Eyrich et al. found that seeding cells into PCL 
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scaffolds through encapsulating them in fibrin gel increased both the seeding efficiency 
and the homogenous matrix distribution.56  Furthermore, both in vitro and in vivo studies 
have shown abundant proteoglycans and type II collagen expression on PCL scaffolds 
seeded with chondrocytes, embryonic stem cells, and bone marrow-derived mesenchymal 
stem cells (with the latter two induced to differentiate down a chondrogenic lineage by 
culture in specific differentiation medias).51, 56-63 Oliveria et al. report better 
biocompatibility compared to PGA scaffolds where they see lack of tissue in center of 
scaffolds possibly due to acidic by products.60  PCL scaffolds have also been applied for 
use in osteochondral sites where studies show promising results in terms of bone growth, 
cartilage growth and integration.64, 65  Here we demonstrate that cartilaginous tissue can 
be produced throughout 3D-designed melt-cast PCL scaffolds when chondrocytes are 
seeded within collagen 1 hydrogel.  
 
Melt-casting of PCL shows promise for use in cartilage tissue engineering research.  
Aside from its mentioned applications for regeneration of articular defects, it also 
provides a cheap, easy, organic-solvent-less fabrication method for studying the effects 
that scaffold architectures, mechanical properties, or surface modifications may have on 
tissue regeneration.   
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CHAPTER 6 
TAILORING THE MECHANICAL PROPERTIES OF 3D-DESIGNED 




6.1 Introduction  
Polymer scaffolds will play a key role in treating cartilage defects, deterioration, and 
damage caused by aging, disease and trauma.  There are a number of synthetic materials 
and a wide range of fabrication methods being applied to make such scaffolds, with the 
general acceptance that these constructs should be biocompatible, biodegradable, and 
mechanically stable.  Here, we focus on the requirement that a scaffold should have 
mechanical properties, particularly tangent modulus values, in the range of native 
cartilage values.  There are two components that determine the final effective scaffold 
stiffness: 1) the base material stiffness and 2) the scaffold pore architecture.  Since pore 
geometry may be restricted by tissue in-growth requirements, it would be advantageous 
to also alter effective scaffold stiffness by altering the base material stiffness. We show 
how the processing conditions of poly(glycerol sebacate) (PGS) can be varied to tailor 
the mechanical properties of three-dimensionally designed, solid-freeform fabricated 
(SFF) scaffolds for cartilage tissue engineering.  
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Poly(glycerol sebacate) has recently been applied for tissue engineering. Synthesis and 
characterization of the polymer, created through a polycondensation reaction of glycerol 
and sebacic acid, was first reported for use in biotechnology and bioengineering in 20021  
to provide good mechanical properties and rubberlike elasticity, established degradation 
and crosslinking mechanisms optimal for soft tissue engineering applications.  Along 
with being tougher, less expensive and more flexible than existing biodegradable 
elastomers, glycerol and polymers containing sebacic acid have been approved by the US 
Food and Drug Administration for medical applications.  To date, PGS has been studied 
for applications in nerve guidance,2  soft tissue regeneration,3, 4  vascular and myocardial 
tissue regeneration,5-9 blood vessel reconstruction,10, 11 drug delivery,12 and in the 
replacement of photoreceptor cells.13   PGS is a biodegradable polymer with 
biocompatibility and mechanical properties that make it well suited for applications such 
as those mentioned above and, as we show here, for use in cartilage tissue engineering.  
 
PGS is processed through first creating a prepolymer, and then curing the prepolymer at 
high temperatures to obtain a thermoset elastomeric polymer.  Most studies have 
fabricated the polymer through conventional methods, creating films or porogen-leached 
sponges.  The most advanced structures reported are tubular sheets and films developed 
as scaffolds for blood vessels renal tubules or various ducts.10, 11   In this work, we 
demonstrate the ability to process PGS using SFF techniques in order to create scaffolds 
with designed pore shapes, pore sizes, porosities, and architectures.  In the past, this 
fabrication has been widely used in our lab in order to make designed scaffolds from 
poly(l-lactide acid), poly(lactic-co-glycolic acid), poly(ε-caprolactone), hydroxyapatite, 
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poly(propylene-fumarate), and poly(propylene-fumarate)/tri-calcium phosphate blends.14-
23  for applications in bone regeneration, spinal cord reconstruction, and cartilage tissue 
engineering. Because most of these materials, when fabricated into 3D designed 
scaffolds, exhibit mechanical properties that are outside the ranges of cartilage, we have 
more recently applied this technology to more elastomeric materials, such as 
poly(glycerol sebacate) (PGS) and poly(1,8-octanedial-co-citrate) (POC) for cartilage 
tissue engineering applications.24  We believe that the mechanical properties of these 
materials make them ideal for use in fabricating scaffolds for load bearing articular sites. 
Fabrication of PGS by this means is not yet reported.  
 
One of the main advantages of using PGS for tissue engineering is that its mechanical 
properties can be tailored to match specific tissue properties through altering processing 
parameters during the prepolymer and/or curing steps. In 2008, Chen et al. demonstrated 
the ability to alter the mechanical properties of PGS for myocardial tissue applications 
through changing curing temperature, recording Young’s modulus values of .056 MPa 
(110°C), .22MPa (120°C), and 1.2MPa (130°C).7  In this work we evaluate how changing 
the molar ratios of glycerol: sebacic acid during pre-polymer synthesis and how changing 
the curing time causes variations in non-linear elastic mechanical properties.  
 
The purpose of this chapter is to assess PGS as a scaffolding material for cartilage tissue 
engineering by determining how synthesis conditions affect both bulk PGS properties and 
those of PGS scaffolds with designed architecture.  Since PGS applications for cartilage 
regeneration have not been previously reported, we further demonstrate that PGS 
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scaffolds support robust cartilage formation when seeded with porcine chondrocytes in 
vitro. 
 
6.2  Materials and Methods 
Fabrication of Solid Cylinders and 3D-designed scaffolds 
Pre-polymer synthesis 
PGS pre-polymer (pPGS) was synthesized following methods described by Gao et al.4   
For this research, three batches of pPGS were synthesized with various molar ratios of 
sebacic acid:glycerol (3:4, 1:1, 4:3).  Sebacic acid and glycerol were reacted under N2 at 
120°C.  After 24 hours, the N2 was removed and a vacuum of 50mTorr was pulled for an 
additional 48 hours, with a condenser attached.  
 
Polymer Curing 
Curing of pre-polymer was done through a modified protocol4  that enabled fabrication of 
designed architecture scaffolds from wax molds.  To create solid cylinders for 
mechanical testing, the pre-polymer was poured into a Teflon mold, and cured for various 
time points (24h w/out vacuum plus 24h, 48h, or 72h with a 100mTorr vacuum).  A 
three-dimensional (3D) scaffold (3mm height, 6.35mm diameter, 1mm spherical pores, 
54% porosity) was designed using custom Interactive Data Language™ programs (IDL; 
Research Systems, Inc., Boulder, CO).15, 16  To fabricate designed scaffolds, pPGS was 
poured into a Teflon mold, and an inverse hydroxyapatite (HA) mold was pressed into 
the pPGS. HA molds were fabricated following a protocol previously established in the 
lab, with inverse HA molds made on a SolidScape printer (SolidScape Inc., Merrimack, 
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NH). 25   The Teflon/pPGS/HA mold unit was placed within a vacuum oven to cure at 
150°C.  For the first 24 hours, no vacuum was pulled, in order to allow the prepolymer to 
begin to cure, preventing air bubbles from forming in the polymer when a vacuum is 
pulled.  After 24 hours, a strong vacuum (100 mTorr) was pulled, and the temperature 
was maintained at 150°C for 24, 48 or 72 hours longer.  The HA+PGS construct was 
removed from the cup, and the HA was dissolved out using a rapid decalcifying agent 
(RDO, Apex Engineering, Aurora, IL) to achieve the final PGS scaffold. The schematic 
of this process was shown in Figure 3.5.  PGS scaffolds and cylinders were autoclaved 
and rinsed overnight in DMEM before mechanical testing or chondrocyte seeding.  Note, 
curing times reported in the results section refer to the hours cured after a vacuum was 
pulled (24, 48 and 72). 
 
Micro-computed tomography image analysis 
In order to assess defects and create images for finite element analysis (FEA), solid 
cylinders and scaffolds were scanned using a MS-130 high resolution µCT scanner (GE 
Medical Systems, Toronto, CAN) at a 16 µm voxel resolution. Scans were performed in 
air at 75 kV and 75 mA.  GEMS Microview software (GE Medical Systems, Toronto, 
CAN) was used to view reconstructed images.   
 
Mechanical Testing  
Solid cylinders and 3D-designed scaffolds were tested in compression using an MTS 
Alliance RT30 electromechanical test frame (MTS Systems Corp., MN).   
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Stress-Relaxation in Confined Compression 
Stress-relaxation tests were performed in confined compression following a protocol 
established by Guilak et al. in 1989 26 and used extensively in the field by others.27, 28  
Briefly, pre-soaked samples were loaded into a confining cylindrical chamber filled with 
a phosphate buffered saline solution controlled at 37°C.  A porous indenter was lowered 
until a reading of .05lb was output on the computer, signifying that the indenter was in 
contact with the cylinder or scaffold.  This load was held for 600s and assumed to be the 
0% strain position.  Under displacement control, stress-relaxation testing was performed 
with a single ramp of 20% strain applied at 0.25 µm/s or 5 µm/min.  The crosshead was 
then held at constant displacement for 30 min to record relaxation.   
 
Unconfined Compression 
Unconfined compression tests were performed on solid cylinders (n = 5-10 for each 
group, with variation in sample size due to exclusion of poorly made cylinders) under 
displacement control.  Samples were compressed to failure in the z-direction between two 
fixed steel platens at a rate of 2 mm/min after a preload of .05 lb was applied.  A single 
set of 3D-designed scaffolds were fabricated (n=7) (1:1 molar ratio, 48h cure time) and 
tested in unconfined compression in order to validate FEA predictions.   
 
Finite Element Analysis  
Complete anisotropic effective stiffness constants were calculated using the voxel-based 
homogenization software VOXELCON (Quint Corp, Tokyo, Japan), as described 
previously in.23  STL design files were converted to .vox files, and PGS modulus values 
 98
from mechanical testing of solid cylinders (3 molar ratios x 3 curing temperatures) were 
input into VOXELCON, with a Poisson’s ratio of 0.3, and run on scaffold designs.   
 
In Vitro Study  
Chondrocyte harvest 
Cartilage was harvested from fresh metacarpophalangeal joints of domestic pigs obtained 
from a local abattoir (Northwest Market, Northwest, MI). Cartilage pieces were digested 
in a digest solution [DMEM high glucose, serum free, 1 mg/ml collagenase II (Sigma # 
C1764), 2% Pen/strep, 2% kanamycin (Roche, 12728700), and .2% Fungizone 
(Invitrogen, 15290-018)] on a stir plate for 6 hours at 37°C, 5% CO2.  The solution was 
then filtered through sterile nylon.  Cells were spun at 2000rpm for 8 minutes, and plated 
overnight on tissue culture polystyrene in DMEM + 10%FBS + 1% P/S + 50 µg/ml 2-
phospho-L-ascorbic acid (BioChemika, 49752).  The following day, cells were 
trypsinized and immediately suspended in collagen gel for scaffold seeding. 
 
Cell seeding and in vitro culture 
PGS scaffolds were sterilized in an autoclave and presoaked in DMEM for 24 hours prior 
to cell seeding. Chondrocytes were suspended in a composite 5% Hyaluronic Acid (HyA) 
(stock concentration: 2.7 mg/ml in 0.8M NaCl, MW: 3 x 106 Da: Hyalogic LLC, 
Edwardsville, KS) info)/collagen I gel (stock concentration: 5.9 mg/ml, BD Biosciences, 
#354236) at ~30 x 106 cells/ml.  4% v/v .5M sodium hydroxide with 220 mg/ml sodium 
bicarbonate was used to increase the pH of the collagen/HyA/cell suspension just before 
seeding into the scaffolds in order to create gelling at 37°C. Cells were evenly seeded into 
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scaffolds by using a custom designed Teflon mold.  After gelling (~30 minutes), 
scaffolds were removed from the mold. Scaffold + Cells + Gel constructs were cultured 
in an incubator (37°C, 5% CO2) in 24-well plates on an orbital shaker for 2 weeks.  
Media (DMEM, 10%FBS, 1% P/S, 0.1mM Non-essential Amino Acids, 50 µg/ml 2-
phospho-L-ascorbic acid, 0.4 mM proline, 5ug/ml insulin) was changed every other day. 
After 2 weeks, scaffolds (n=2) were removed, fixed in 10% buffered formalin phosphate  
(Fisher, SF100-20) overnight, dehydrated in EtOH washes, and paraffin embedded. 
Sections were stained with Alcian Blue to illustrate GAG production. 
 
sGAG quantification 
At 2 weeks, scaffolds (n=3) were removed from culture, finely chopped, and placed 
immediately into 1 ml of papain solution (papain, 1X PBS, cysteine HCL, EDTA, 
pH=6.0; mixed for 3h at 37°C then filtered).  Scaffolds were digested in papain for 24 
hours and then immediately frozen at -20°C.  A DMMB assay was run on digested 
scaffolds.  Briefly, 20ul of sample was mixed with 200ul of dimethylmethylene blue 
reagent and absorbance was immediately read on a plate reader (MultiSkan Spectrum, 
Thermo, Waltham, MA) at 525 nm.29  Readings were compared to a standard curve 
established from chondroitin 6-sulfate from shark  (Sigma, C4384). 
 
DNA Quantification 
Papain digested scaffolds were also used to determine DNA content through a Hoechst 
33258 Assay (Sigma, #861405).  Briefly, 100ul digested sample was added to 100ul 
Hoechst and read with excitation: 355nm, emission: 460nm (Fluoroskan Ascent FL, 
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Thermo, Waltham, MA) in a 96 well plate.  Readings were compared to standards made 
from calf thymus DNA (Sigma, #D0805). 
 
Quantitative-PCR 
qtPCR was used to determine the expression of cartilage specific genes (collagen II and 
aggrecan), a chondrocyte dedifferentiation marker (collagen I) and a house-keeping gene 
(GAPDH). Scaffolds were removed from culture, rinsed twice with PBS, cut into small 
pieces (~1mm3), and placed immediately into RNAlater (Qiagen, D-40724). Scaffolds 
were incubated RNAlater at 4°C for 24 hours then transferred to -20°C for storage.  For 
RNA extraction, scaffold + tissue were homogenized in Buffer RLT for approximately 60 
seconds.  Lysate was then centrifuged, and supernatant was removed. RNA was extracted 
using an RNeasy Mini Kit (Qiagen #74104), and samples were stored at -80°C.  After 
measurement of RNA concentration for each sample, first-stand cDNA was synthesized 
using random primers (Superscript Kit #18064).  Samples were prepared for qtPCR using 
a Taqman universal PCR master mix (Applied Biosystems, 4304437) and custom 
designed porcine primers.  qtPCR was then performed using an ABI PRISM 7700 
(Applied Biosystems, Foster City, CA 94404, U.S.A). As a control, prior to seeding, 
5x106 chondrocytes were incubated in RNAlater and used for qtPCR.   
 
Statistical Analysis  
Multiple linear regression was performed using SPSS software (SPSS for Windows, Rel 




Fabrication of cylinders and scaffolds  
Micro-CT analysis of solid cylinders confirmed the absence of air bubble defects in these 
mechanical testing specimens.  Successful fabrication of designed scaffolds can be seen 
in Figure 6.1, where µCT analysis of scaffolds, again, confirms the absence of defects 
(Figure 6.1 a/b). Volume fraction quantification done on µCT images reveals that the 
porosity of fabricated scaffolds (48.1 ± 4.24 %) is slightly less than that of the design file 
(54%), while scaffold pore diameters (1.04 ± .04 mm) are equal to designed pore sizes 
(1.0 mm).  Decreased porosity of actual scaffolds is most likely due to small amount of 
PGS penetrating into pores. 
 
1 mm 1 mm
1 mm 1 mma b
c d  
Figure 6. 1 Successfully fabricated 3D-designed PGS scaffolds illustrated through microCT images, 
side view (a) and top view (b) and digital images, side view (c) and top view (d). 
 
Mechanical Property Variations  
Stress-relaxation testing done on solid cylinders (n=2 for each molar ratio/cure time) 
revealed that PGS does not exhibit typical viscoelastic responses.  Stress-relaxation 
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profiles were not dependent on strain rate (.25 um/sec v. 5 µm/sec), nor did they relax 
under constant displacement after loading (Figure 6.2), indicating that PGS exhibited 
predominantly elastic properties and therefore, PGS bulk and scaffolds were tested in 
unconfined compression and fit to a 1D nonlinear elastic model commonly used for 
biological soft tissues: 
( )1BT A e ε= −  
where T is the 1st Piola-Kirchoff stress, ε is the large strain, and A and B are model 
parameters fit to experimental data.  The fit was performed using a specially written 
MATLAB program calling the optimization function fminunc.  The tangent modulus at 
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Figure 6.2.  Stress vs. strain (a) and stress versus time (b) response of PGS cylinders and scaffolds (c) tested in 
stress relaxation demonstrates that they do not exhibit the typical viscoelastic response of cartilage (d) as shown 
by Soltz and Ateshian.27   
 



























Figure 6.3.  1D nonlinear elastic model provides good fit for solid PGS cylinders (a) and 3D-designed 
scaffolds (b).  
 
As seen in Figure 6.4, the tangent elastic modulus of PGS is significantly altered through 
variations in pre-polymer molar ratios and curing times.  Multiple regression provided a 
powerful (adjusted R2 = .70, predictive power = 70%) linear equation for tangent 
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modulus (at 10% strain) dependent on these two variables: y = 3.607 – 1.410 * (molar 



























































Figure 6. 4.  Tangent Modulus (at 10% strain) values for PGS cylinders with various processing 
parameters.  Linear regression can be used to predict the modulus (70% power) from these two 
variables: Modulus (MPa) = 3.607 – 1.410 * (ratio of glycerol: sebacic acid) + 0.60 * (vacuum curing 
time in hours).  
 
Finite Element Analysis 
FEA was used to calculate the tangent elastic modulus values of scaffold design files and 
µCT images of actual scaffolds using values of solid cylinder tangent modulus at 10% 
strain.  Table 6.1 displays experimental modulus values of solid cylinders, FEA 
predictions of modulus values for a 3D scaffold from design files, and modulus values 
from experimentally tested scaffolds.  The voxel model is able to accurately predict the 
tangent modulus of scaffolds from the design file (prediction = 0.60 MPa, actual = 0.57 ± 
0.24).   
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Table 6.1.  Modulus values of solid PGS cylinders made from varying glycerol:sebacic acid molar 
ratios and varying curing times were used in FEA to predict the modulus value of scaffolds that 
could be made using the same conditions.  Scaffolds were tested experimentally to verify predictions. 










24  2.34 ± 0.83 7 1.73 ± 0.92 10 0.13 ± 0.12 5 0.62 0.46 0.03    
48  3.05 ± 0.71 9 2.29 ± 0.61 10 0.40 ± 0.17 8 0.81 0.60 0.11  0.57 ± 0.24  
72  4.28 ± 1.15 8 2.82 ± 0.49 8 0.71 ± 0.38 7 1.13 0.75 0.19    
  3:4 1:1 4:3 3:4 1:1 4:3 3:4 1:1 4:3 
  Molar Ratio (glycerol: sebacic acid) 
*Sample size (n) is displayed in superscript for each group. 
 
In Vitro Study 
Chondrocytes suspended in collagen 1 hydrogel within 3D designed scaffolds maintained 
a rounded morphology and were able to produce a cartilaginous matrix as seen in digital 
images and through alcian blue staining in Figure 6.5.  Sulfated-GAG concentrations 
were within the same ranges as chondrocytes cultured under identical conditions on 
poly(ε-caprolactone) (PCL) of the same architectural design (29.64 ± 11.87 vs. 33.00 ± 
6.24 µg GAG/µg DNA, respectively) (n=3).  Collagen 2: collagen 1 ratios were higher 
for chondrocytes cultured on PGS than those cultured under identical conditions on PCL 
(20.91 ± 3.25 vs. 8.69 ± 0.17), but were lower than mRNA expression by unseeded 
chondrocytes (267). Aggrecan expression by cells on PGS was similar to cells seeded on 
PCL (1.74 ± 0.68 vs. 1.67 ± 0.07), and both expression levels were higher than expressed 







Figure 6.5. Digital images and histological sections (stained with alcian blue) show in vitro growth of 
cartilaginous tissue into PGS scaffolds. 
 
 
6.4  Discussion and Conclusion  
We have presented a novel PGS fabrication method.  Actual scaffold pore sizes and 
porosities show no major deviations from design files, and there is no significant swelling 
of solid cylinders or scaffolds when they are soaked in DMEM or PBS.   
 
It is highly desirable to be able to synchronize biomimetic mechanical properties of a 
scaffold with architectures designed for optimal tissue regeneration.  Intuitively, one way 
in which the mechanical properties of a scaffold can be altered is through changing the 
structural features, such as pore size, porosity, interconnectivity, and pore shape.15, 30   
However, changing these features also has an effect on cartilage tissue regeneration. 31-36     
Working with a material that’s intrinsic elastic properties can be altered enables 
fabrication of scaffolds with a wide range of architectures (designed for optimal tissue 
regeneration) from one material, all of which will support in vivo loads.  As shown here, 
PGS is beneficial in this respect, as its mechanical properties can be varied simply 
through changing the molar ratios of glycerol to sebacic acid during pre-polymer 
synthesis or varying the duration of curing.   
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After establishing a collection of bulk mechanical properties for nine processing 
combinations (3 molar ratios x 3 curing times), we used FEA to predict the elastic moduli 
of a 3D designed scaffold fabricated from these various batches of PGS.  A single batch 
of scaffolds, fabricated from an intermediate of the nine processing combinations, 
verified that modulus values reported through FEA are reasonable estimates.  This 
demonstrates the ability of image-based FEA to compute the effective stiffness of PGS 
scaffolds without the need for destructive testing.   
 
Although PGS does not exhibit viscoelastic properties, the ability to match the elastic 
modulus of scaffolds to the elastic component of cartilage is a step in the right direction.  
There is no data that indicates how critical it is to match all cartilage properties exactly to 
achieve good mechanical support and regeneration.  A current clinical treatment, 
autologous chondrocyte implantation, has shown success without any substantial 
mechanical support.37   However, patients must be extremely careful not to overload the 
delicate periosteal flap which envelopes the repair site.  This draws a thin line between 
the amount of post-operative mechanical loading shown to enhance tissue regeneration, 
and the amount that will damage the graft.38  Furthermore, this data can be applied to 
other soft tissue engineering applications that PGS is being studied for, such as 
myocardial tissue7 , where non-linear elastic properties are highly desirable.  
 
The elastic component of experimental cartilage data can be separated out using the 








where, HA is the aggregate modulus, E is the elastic component of this modulus, and v is 
the Poisson’s ratio.  Poisson’s ratio was assumed to be 0.3, as experimentally measured 
by Cohen et al.  With literature showing HA values of healthy cartilage ranging from .089 
MPa to 2.22 MPa,27, 28, 39-47  the calculated elastic component ranges from 0.04 to 0.99 
MPa.  Elastic modulus values predicted for this particular scaffold design from the 
collection of PGS bulk properties, range from 0.03 to 1.13 MPa, completely 
encompassing the native tissue values that one might wish to match.  
 
Furthermore, an in vitro experiment shows that PGS can indeed be used for cartilage 
tissue engineering applications where chondrocytes are seeded within a scaffold to 
produce a cartilaginous matrix.  Aggrecan is expressed in higher levels on PGS scaffolds 
than in pre-seeded cells, showing favorable trends toward chondrogenesis.  Collagen 2: 
collagen 1 ratio, commonly referred to as a “differentiation index” for chondrocytes,48  
where a larger values represents more chondrogenic gene expression and a lower value 
represents more fibroblastic gene expression, is higher on PGS than on identical studies 
done using PCL. Differences between expression levels on PGS versus PCL may be 
related to the hydrophilicity of PGS.  Increased material hydrophilicity may enhance cell 
adhesion, retain more sGAG, and more closely mimic the native hydrophilic nature of 
cartilage ECM, however further studies need to be done in order to verify this hypothesis.   
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PGS is a good candidate for cartilage tissue engineering applications. As shown for the 
first time, it can be fabricated into 3D designed scaffolds using SFF techniques and is 
biocompatible with chondrocytes in vitro.  Its bulk mechanical properties can be altered 
during synthesis and curing in order to match stiffness values of 3D-designed scaffolds to 
those of native cartilage.  Furthermore, scaffold modulus values can be predicted using 
FEA, eliminating the need for destructive testing on custom scaffolds.   
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CHAPTER 7 
THE EFFECTS OF SCAFFOLD PERMEABILITY ON CHONDROGENESIS 




Advancements in cartilage tissue engineering are being made through the use of 
biodegradable scaffolds.  In order for this field to progress, it is important to characterize 
structural and physical scaffold properties that affect the enhancement and maintenance 
of new cartilage formation.  It is widely proposed that scaffold permeability influences 
chondrogenesis. However, there is no definitive conclusion as to how permeability 
affects cartilage regeneration, as it has not been rigorously controlled. Here, we 
investigate the in vitro effects of scaffold permeability on matrix production and cellular 
differentiation of chondrocytes and bone marrow stromal cells (BMSCs) using designed 
poly(e-caprolactone) (PCL) scaffolds with rigorously controlled permeability. 
 
It has been proven that permeability is a physical design parameter that can be used to 
describe the impact that complicated structural properties such as pore size, pore shape, 
interconnectivity, pore distribution, fenestration size and distribution, and orientation of 
pores have on mass transport within a scaffold.1   Particularly for cartilage tissue 
engineering, this is an interesting design parameter to study.  In more metabolically 
active tissues, such as bone, it is generally accepted that an increase in permeability 
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correlates with an increase in tissue growth.  However, this contradicts a number of 
findings for cartilage.  Clinically, native articular cartilage exhibits relatively low 
permeability in comparison to bone, increases in permeability are correlated with disease 
and deterioration, and decreases in permeability with tissue depth correlates with a rise in 
proteoglycan content.2  Knowing that oxygen and nutrient diffusion are governed by 
scaffold permeability3, there is further evidence that scaffolds designed with decreased 
permeability may enhance cartilage tissue regeneration:  First, native chondrocytes live in 
a low oxygen environment21-23, and it is proposed that increases in oxygen may result in 
disturbance to chondrocyte metabolism through production of abnormal levels of reactive 
oxygen species (ROS).  This is evidenced in osteoarthritic tissue, where ROS are 
produced in greater amounts resulting in oxidative stresses that cause deterioration of 
tissue.4  Secondly, in tissue engineering studies, cartilage grows in anaerobic conditions 
where oxygen diffusion is low.5-7 And finally, imposing a low oxygen level in in vitro 
conditions  has been shown to significantly influence the regenerative potential of 
chondrocytes and BMSCs in monolayer and 3D culture.8-25     
 
In this chapter, we examine how the physical property of permeability, as described by 
Darcy’s law, affects chondrocytes or bone marrow stromal cells seeded onto PCL 
scaffolds and cultured in vitro, with the hypothesis that this parameter can be used to 
more accurately predict the effects of scaffold architecture on chondrogenesis.  We 
believe that because scaffold permeability affects diffusion, oxygen tension, and nutrient 
exchange it will impact cellular differentiation and cartilaginous tissue production on 
biodegradable scaffold, and should be regarded as an independent design consideration.  
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In order to pursue this hypothesis, we use SFF techniques to create 3D-designed poly(ε-
caprolactone) scaffolds with significantly different permeability values.  Because 
structural properties such as pore size, pore shape, and interconnectivity have been shown 
to affect chondrogenesis, these properties were kept consistent in our designs.  Variations 
in permeability were created through changing the diameter of the interconnection 
between pores.  Scaffolds were seeded with bone marrow stromal cells or chondrocytes 
and cultured in vitro for up to 6 weeks in order to examine the effects that permeability 
has on cellular differentiation and matrix production of these cells.  
 
7.2  Materials and Methods 
Scaffold Design, Fabrication, and Characterization 
Scaffold Design 
Three-dimensional (3D)-designed scaffolds (3mm height, 6.35mm diameter, 1mm 
spherical pores) were designed using custom Interactive Data Language™ programs 
(IDL; Research Systems, Inc., Boulder, CO).  Scaffolds were designed such that the 
throat size between pores was the only structural difference between scaffolds, creating 
“low”, “mid” and “high” permeable designs.  
 
Scaffold Fabrication 
Inverse wax molds of designs were processed on a Solidscape MM2 3D printer 
(SolidScape Inc., Merrimack, NH). Scaffolds were made by pressing these wax molds 
directly into melted 37kDa polycaprolactone (CAPA 6400, Solvay Caprolactones, 
Warrington, Cheshire, UK).  Briefly, PCL pellets were placed into a Teflon mold, and 
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melted (115°C, 1 Torr, 120 minutes). After melting and air bubble removal, the Teflon 
mold was pulled from the oven, and allowed to cool for 270 seconds at room 
temperature, reaching 80°C (just below the melting temperature of the wax molds).  At 
this time, inverse wax molds were pressed into the melted PCL, and the entire construct 
was cooled overnight.  Wax was dissolved from the PCL using 100% EtOH.  A 
schematic of this process was shown in Figure 3.3. 
 
Computational Permeability Measurement 
An image based homogenization theory program, that combines Darcy’s Law and the 
Navier-Stokes equation, was used in order to compute permeability, K, as defined by: 
Kij=1/µ [νji] (m3/N·s), where µ=fluid viscosity and ν=velocity field.26    
 
Experimental Permeability Measurement 
A custom permeability chamber was designed (Appendix B) to exert a constant hydraulic 
pressure on a scaffold. Water flow through the chamber and into a secondary container 
placed atop a scale (Ohaus Scout Pro) connected to a PC was continually recorded.  
Within LabView (National Instruments, Austin, TX), an equation derived from 
Bernoulli’s equation (with a frictional loss correctional term) and Darcy’s Law, as 
described by Li and Mak,27 was used to compute permeability: 
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where k=permeability (m4/N·s), ∆x = length of scaffold (m), A = cross-sectional area of 
scaffold (m), MB1=Mass flow rate without scaffold (g/s), MB2=Mass flow rate with 
scaffold (g/s), r = radius of water outlet (m).  Labview recorded 3 readings per second, 
giving a continuous output of permeability.  Permeability data was plotted to validate that 
the permeability level was constant throughout the experiment. The data was then 
averaged to obtain experimental scaffold permeability.  Scaffolds were tested in the 
chamber with and without collagen gel incorporated. 
 
Porosity, Pore Size, Interconnection Size Measurement 
Fabricated scaffolds were scanned dry using a MS-130 high resolution micro-computed 
tomography (µCT) scanner (GE Medical Systems, Toronto, CAN) at 16 µm voxel 
resolution, 75kV and 75mA.  GEMS Microview software was used to analyze the images 




Stress-relaxation tests were performed in confined compression following a protocol 
established by Guilak et al. in 1989 28 and used extensively in the field by others.29, 30  
Briefly, pre-soaked samples were loaded into a confining cylindrical chamber filled with 
a physiological saline solution controlled at 37°C.  A porous indenter was lowered until a 
reading of .15 lb was output on the computer, signifying that the indenter was in contact 
with the scaffold.  This load was held for 600s and assumed to be the 0% strain position.  
Under displacement control, stress-relaxation testing was performed with a single ramp 
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of 10% strain applied at 0.25 µm/s, followed by a 30 min relaxation.  Data obtained from 
stress relaxation testing was fit to a two-term prony series program in MATLAB to 
determine relaxation parameters and equilibrium aggregate modulus.   
   
In Vitro Experimentation 
Chondrocyte Harvest 
Cartilage was harvested from fresh metacarpophalangeal joints of domestic pigs obtained 
from a local abattoir (Northwest Market, Northwest, MI). Cartilage pieces were stirred in 
a digest solution [DMEM high glucose, serum free, 1 mg/ml collagenase II (Sigma # 
C1764), 2% Pen/strep, 2% kanamycin (Roche, 12728700), and .2% Fungizone 
(Invitrogen, 15290-018)] for 6 hours at 37°C, 5% CO2.  The solution was then filtered 
through sterile nylon.  Cells were spun at 2000 rpm for 8 minutes, and plated overnight 
on tissue culture polystyrene in DMEM + 10%FBS + 1% P/S + 50 µg/ml 2-phospho-L-
ascorbic acid (BioChemika, 49752).  The following day, cells were trypsinized and 
immediately suspended in collagen gel for scaffold seeding. 
 
Bone Marrow Stromal Cell Harvest 
Bone marrow was harvested at the Seguin Animal Hospital (Seguin, TX) from the hip of 
a Yucatan Mini Pig (Lone Star Laboratory Swine) and placed into media 
(DMEM+10%FBS+2% P/S+.2%Fungizone + .1% Gentamycin + 200 units/ml Heparin) 
for overnight shipment on ice to the University of Michigan. Bone marrow aspirate was 
placed into tissue culture flasks upon arrival.  Half of the media (DMEM + 2% P/S + .2% 
Fungizone + 10% FBS) was changed on day 7 and day 11. On day 14, cells were 
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passaged and then grown to 80% confluence, at which point they were frozen in liquid 
nitrogen for later use. 
 
Cell Seeding 
Scaffolds were sterilized in 100% Ethanol for 24 hours, followed by rinses in sterile 
water (12 hours) and DMEM (4 hours) prior to seeding.  Chondrocytes or BMSCs were 
suspended in a composite 5% Hyaluronic Acid (HyA) (stock concentration: 2.7 mg/ml in 
0.8M NaCl, MW: 3 x 106 Da: Hyalogic LLC, Edwardsville, KS) info)/collagen I gel 
(stock concentration: 5.9 mg/ml, BD Biosciences, #354236) at ~30 x 106 cells/ml.  Cells 
were evenly seeded into scaffolds using a custom designed Teflon mold.  Due to 
variances in the porosity, a different volume of collagen gel (calculated from void area) 
and a different cell number was seeded into each design in order to maintain a consistent 
cell seeding density (Low: 1.25 x 106 cells/scaffold, 47µl gel; Mid: 1.93 x 106 
cells/scaffold, 59µl gel; High: 2.2 x 106 cells/scaffold, 71µl gel). 4% v/v .5M sodium 
hydroxide with 220 mg/ml sodium bicarbonate was used to increase the pH of the 
collagen/HyA/cell suspension just prior to scaffold in order to create gelling at 37°C. 
After gelling (~30 minutes), scaffolds were removed from the mold.  
 
In Vitro Culture 
Scaffold + Cells + Gel constructs were cultured in an incubator (37°C, 5% CO2) in 24-
well plates on an orbital shaker for up to 6 weeks.  Media (Chondrocyte Scaffolds: 
DMEM, 10%FBS, 1% P/S, 0.1mM Non-essential Amino Acids, 50 µg/ml 2-phospho-L-
ascorbic acid, 0.4 mM proline, 5ug/ml insulin or BMSC Scaffolds: DMEM, 10%FBS, 
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1% P/S, 0.1mM Non-essential Amino Acids, 50 µg/ml 2-phospho-L-ascorbic acid, 0.4 
mM proline, 5ug/ml insulin, 10ng/ml TGF-β, and .1 µM dexamethasone) was changed 
every other day.  At each time point, scaffolds were extracted for DMMB and Hoechst 
(Chon: n=5, BMSC: n=4), qtPCR (Chon: n=2, BMSC: n=4) and histology (Chon: n=2, 
BMSC: n=2).   
 
sGAG Quantification 
At 2, 4 or 6 weeks, scaffolds were removed from culture, finely chopped, and placed 
immediately into 1 ml of papain solution (papain, 1X PBS, cysteine HCL, EDTA, 
pH=6.0; mixed for 3h at 37°C then filtered).  Scaffolds were digested in papain for 24 
hours and then immediately frozen at -20°C.  A DMMB assay was run on digested 
scaffolds.  Briefly, 20ul of sample was mixed with 200ul of dimethylmethylene blue 
reagent and absorbances were immediately read on a plate reader (MultiSkan Spectrum, 
Thermo, Waltham, MA) at 525 nm.31  Readings were compared to a standard curve 
established from chondroitan 6-sulfate from shark  (Sigma, C4384). 
 
DNA Quantification 
Papain digested scaffolds were used to determine DNA content through a Hoechst 33258 
Assay (Sigma, #861405).  Briefly, 100ul digested sample was added to 100ul Hoechst 
and read with excitation: 355nm, emission: 460nm (Fluoroskan Ascent FL, Thermo, 
Waltham, MA) in a 96 well plate.  Readings were compared to standards made from calf 
thymus DNA (Sigma, #D0805). 
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Quantitative-Polymerase Chain Reaction (qtPCR) 
qtPCR was used to determine the expression of cartilage specific genes (collagen II and 
aggrecan), a chondrocyte dedifferentiation marker (collagen I) and a house-keeping gene 
(GAPDH). Scaffolds were removed from culture, rinsed twice with PBS, cut into small 
pieces (~1mm3), and placed immediately into RNAlater (Qiagen, D-40724). Scaffolds 
were incubated (4°C for 24 hours) and then stored (20°C) in RNAlater.  For RNA 
extraction, scaffold + tissue were homogenized in Buffer RLT for approximately 60 
seconds.  Lysate was then centrifuged, and supernatant was removed. RNA was extracted 
using an RNeasy Mini Kit (Qiagen #74104), and samples were stored at -80°C.  After 
measuring RNA concentration for each sample, first-stand cDNA was synthesized using 
random primers (Superscript Kit #18064).  Samples were prepared for qtPCR using a 
Taqman universal PCR master mix (Applied Biosystems, 4304437) and custom designed 
porcine primers.  qtPCR was then performed on an ABI PRISM 7700 (Applied 
Biosystems, Foster City, CA 94404, U.S.A). As a control, 5x106 chondrocytes and 5x106 
BMSCs were also used for qtPCR.  Just before the scaffold seeding step, these cells were 




Paraffin embedded histological sections were stained with Alcian Blue (chondrocyte 





Statistical analysis, including one-way ANOVA, linear regression, and fixed-effect 
modeling, was performed using SPSS software (SPSS for Windows, Rel 14.0. 2005 
Chicago: SPSS Inc.).  
 
7.3 Results 
Scaffold Design, Fabrication, and Characterization 
Scaffolds were fabricated from polycaprolactone. As discussed in chapter 3, PCL 
degrades very slowly, making it an ideal choice for studies where changes in scaffold 
architecture caused by degradation would alter mass transport properties throughout the 
study. Because parameters such as interconnectivity, pore size, and pore shape have all 
been shown to have an effect on cartilage regeneration, scaffolds for this study were 
designed with a consistent pore size (diameter = 1mm), a consistent pore shape 
(spherical) and 100% interconnectivity.  Spherical pore shape was chosen for this study 
because previous work in the lab shows that cells (chondrocytes and BMSCs) cultured in 
these pores produce more robust ECM with higher sGAG concentrations in comparison 
to cubical pores. These finding were attributed to increased local cell densities 
(chondrocytes) or induction of cellular condensations (BMSCs).  Variations in 
permeability were created through altering the throat diameter (0.31, 0.46, 0.55 mm) 
between pores, as seen in Figure 7.1.  
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a b c
1 mm 1 mm 1 mm
.31 mm .46 mm .55 mm
 
Figure 7.1.  Surface rendering of scaffold design (top) and 2x2 unit cells (middle) and digital images 
of fabricated scaffolds for low (a), mid (b), and high (c) permeable designs.  
  
Computationally and experimentally measured structural scaffold properties can be seen 
in Table 7.1. Actual scaffold porosity, pore size, and interconnective size were lower than 
designed sizes due to contraction of the PCL material in ethanol (see Chapter 5).   
Table 7.1.  Computationally designed and experimentally measured (µCT) structural scaffold 
properties.  
StructuralScaffold Properties Low Permeability Mid Permeability High Permeability
Porosity (designed) 53% 63% 70%
Porosity (actual) (n=5) 30% ± 0.89 47% ± 3.41 59% ± 1.75
Pore size (designed) (mm) 1.00 1.00 1.00
Pore size (actual) (mm) (n=5) 0.75 ± .02 0.80 ± .02 0.86 ± .02
Interconnection size (designed) (mm) 0.39 0.54 0.61
Interconnection size (actual) (mm) (n=5) 0.22 ± 0.03 0.30 ± 0.03 0.38 ± 0.03  
 
Computational permeability measurements confirmed differences between scaffold 
designs, labeled as “low”, “mid” and “high” in reference to design permeability.  Next, 
difference in permeability was experimentally verified in a permeability chamber.  After 
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determining that fabricated scaffolds were significantly different between designs (one-
way ANOVA, p ≤ .05), collagen 1 hydrogel was incorporated into scaffolds to 
recapitulate the in vitro seeding protocol.  With gel, scaffold permeability values dropped 
to ~20% of the original scaffold experimental value and continued to exhibit significant 
differences (one-way ANOVA, p ≤ .05) between designs, with experimental permeability 
now matching closely with computationally predicted values (Table 7.2 and Figure 7.2). 
Furthermore, linear correlations between computationally predicted permeability values 
and experimental values (with and without collagen gel incorporation) allow for more 
accurate prediction of actual scaffold permeability from computational design files in the 
future (Figure 7.3).  
 
Table 7.2. Computational and experimental permeability measurements on design files, scaffolds, 
and scaffolds with gel show significant differences between designs.  
Design
Low 0.69 (Low) (Low) (Low)
Mid 2.34 (3.4 x Low) (2.5 x Low) (1.7 x Low)
High 3.99 (5.8 x Low) (5.25 x Low (5.5 x Low)
Permeability (x 10-7 m3/N·s)
7.40 ± 1.40 1.11 ± 0.33
15.37 ± 2.81 3.60 ± 2.23
Computational Experimental (n=6) Experimental (with gel) (n=5)













































































Figure 7.2  Experimental permeability of scaffold designs (Low, Mid, High) were significantly 
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Figure 7.3 Linear correlation between computationally predicted permeability (y = 3.77x – 0.25, R2 = 
0.97) and experimental permeability (y = 0.89x – 0.29, R2 = 0.86) allows computational design of 
scaffolds that meet target experimental permeability values.  
 
Mechanical Properties 
The importance of mechanically testing PCL at 37°C is described in Chapter 5, where it 
is also demonstrated that PCL exhibits a viscoelastic mechanical response.  Here, we find 
that the aggregate modulus of low (8.71 ± 1.06 MPa), mid (5.76 ± 1.24 MPa) and high 
(3.09 ± 0.77 MPa) scaffold designs are higher than the generally accepted ranges of 
articular cartilage (0.5 – 1.0 MPa ).   
 
In vitro experimentation 
Chondrocyte Study  
Chondrocytes proliferated and produced cartilaginous matrix during the 4 week in vitro 
culture period (Figure 7.4).  Live cell numbers increased from (.53 to 1.5 x 106, 283%), 
(.50 to 1.49 x 106, 310%), (.49 to 1.18 x 106, 254%) for low, mid and high designs 
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Figure 7.5. Chondrocyte proliferation on 3D designed scaffolds over 4 weeks of in vitro culture. 
 
Sulfated-glycosaminoglycan (sGAG) content, measured through a DMMB assay, is used 
to quantify cartilaginous matrix production by chondrocytes.  At 2 weeks, there is a trend 
of decreasing sGAG content as scaffold permeability increases.  At 4 weeks, the lowest 
permeable scaffold displays a significant increase in GAG content, measured in regards 
to sample or DNA content, versus the mid and high permeable designs  (one way 
ANOVA, *p ≤ 0.05) (Figure 7.6).   These data suggest that a lower permeable scaffold 


















































































Figure 7.6. GAG content, a) per DNA content and b) per sample, measured on low, mid, and high 
permeable scaffolds seeded with chondrocytes after 2 and 4 weeks of in vitro culture (One Way 
ANOVA, *p ≤ 0.05). 
 
Quantitative-PCR can be used to measure the messenger RNA expression for proteins 
found in cartilage. It is assumed that mRNA expression correlates with downstream 
cellular protein expression.  First, we use this method to quantify the amount of aggrecan 
that chondrocytes seeded with our scaffolds express.  Aggrecan is the main proteoglycan 
found in cartilage, and is a typical marker of differentiated chondrocytes. As seen in 
Figure 7.7, aggrecan is expressed by chondrocytes cultured within scaffolds, but there is 
no significant difference between scaffold design groups at both the 2 week and 4 week 
time point. For comparison, pre-seeded chondrocyte expression normalized to GAPDH 













Figure 7.7.  Aggrecan expression by chondrocytes within 3D designed scaffolds is higher than that 
expressed by pre-seeded chondrocytes (dotted line), but is not significantly different  between 
designs.  
 
Quantitative-PCR was also used to measure collagen expression by cells.  Type two 
collagen is the major fibrillar collagen of articular cartilage, accounting for 90-95% of the 
overall collagen content.32   This gene is localized to cartilage, the vitreous of the eye, the 
nucleus pulposus of intervertebral discs and the embryonic chick primary corneal stroma.  
It provides cartilage with its tensile strength and immobilizes proteoglycans within its 
matrix. Collagen 1, generally associated with bone, tendons, and ligaments, is found in 
small amounts in human articular cartilage and increasing amounts in fibrocartilages, 
presumably contributing to the functional requirements of the tissues.  Its level of 
expression is commonly used as a marker of chondrocyte dedifferentiation.  As a ratio, 
the expression of collagen 2: collagen 1 is termed the “differentiation index” with a larger 
value correlating with a more chondrocytic genotype, and a lower values correlating with 
more fibroblastic gene expression.33   From 2 to 4 weeks, both the low and mid 
permeable designs show an increase in collagen 2: collagen 1 expression (Figure 7.8).  At 
4 weeks, there appears to be a linear relation (linear regression, p = .02) between 



















































permeability correlates with an increase in the chondrogenic differentiation index. For 
comparison, collagen 2: collagen 1 expression by pre-seeded chondrocytes normalized to 

















































































Figure 7.8  Low and mid permeable designs show an increase in collagen 2: collagen 1 expression 
between 2 and 4 weeks.  At 4 weeks there appears to be a linear relation between increasing scaffold 
permeability and decreasing “differentiation index”. 
 
Bone Marrow Stromal Cell Study 
Bone marrow stromal cells, mesenchymal stem cells derived form the bone marrow, are a 
precursor to chondrocytes.  They can be “pulsed” down a chondrogenic lineage through 
the use of specific nutrients in culture media.5   Their use on cartilage tissue engineering 
scaffolds would eliminate the need to harvest chondrocytes from a healthy joint surface.  
They are also unproblematic in monolayer culture and have a higher mitotic potential at 
increased age than chondrocytes.  Figure 7.9 illustrates the rounded morphology of 
BMSCs pulsed in chondrogenic media on 3D scaffolds, suggesting successful pulsing of 






Figure 7.9. Fast green staining of BMSCs after 2 weeks in vitro culture in chondrogenic media  shows 
a more rounded, chondrogenic morphology on 3D scaffolds.  
 
In contrast to chondrocytes, BMSCs encapsulated in collagen 1 hydrogel and seeded into 
3D designed scaffolds show a decrease in live cell numbers between 0 and 2 weeks 
(Figure 7.10).  Because these cells naturally have a higher metabolic requirement than 
chondrocytes it is likely that cell death as quantified between 0 and 2 weeks (40%, 
average of all designs), occurred within the first couple of days after seeding. After this 
initial period, cells proliferated, with cell increases of (.37 to .64 x 106, 173%), (.40 to .63 
x 106, 156%), (.53 to .83 x 106, 157%) between 2 weeks and 6 weeks for low, mid and 















































Figure 7.10. BMSCs are less robust than chondrocytes when seeded into PCL scaffolds, showing 40% 
cell death between 0 and 2 weeks. 
 
 132
Production of cartilaginous matrix by BMSCs, as quantified by sGAG content in 
scaffolds or and sGAG content normalized to DNA content, increases over time, but 
there is no significant differences between groups (Figure 7.11).   This suggests that 
BMSCs have differentiated down the chondrogenic lineage, but that there is no relation 































































Figure 7.11.  BMSCs produce cartilaginous matrix on scaffolds, as evidenced by sGAG production, 
but there is no significant difference in regards to scaffold permeability.  
 
Expression of aggrecan by BMSCs further demonstrates their differentiated state.  As 
seen in Figure 7.12, aggrecan expression increases for all designs from 2 to 4 weeks, 
where thereafter it remains the same or decreases slightly. For comparison, aggrecan 









































Figure 7.12.  Aggrecan expression by BMSCs is higher than pre-seeded BMSCs and further confirms 
their chondrogenic differentiation.  
 
Collagen type two expression can be used as a sensitive marker for chondrogenic 
differentiation of precursor cells, and may coincide with an irreversible commitment to 
chondrogenesis.34   In this study, we looked at the differentiation index (ratio of collagen 
2: collagen 1 expression) of BMSCs between low, mid and high permeable scaffolds at 2, 
4, and 6 weeks.  Using a fixed effect statistical model, overall design effects reveal that 
an increase in permeability (as correlated to each design), results in a 1.1 increase in the 
chondrogenic index (Figure 7.13a).  This same model reveals that over time, the low 
permeability design shows no significant increase in, but rather a trend for decrease in 
collagen 2: collagen 1 ratio (∆ -0.2, p = 0.8).  The mid permeable design shows a non-
significant trend towards increases in differentiation index (∆ 1.33, p = 0.32) over time.  
And finally, the high permeability design shows a significant increase in the 
differentiation index over time (∆ 2.7, p ≤ 0.05) (Figure 7.13b). This data suggests that 
BMSCs favor a higher permeable scaffold environment when cultured in 3D designed 







































































∆ 2.7, p ≤ 0.05
∆ 1.33, p = 0.32
∆ -0.2, p = 0.80












































Figure 7.13.  Collagen 2: collagen 1 expression by BMSCs shows that they favor a more permeable 
scaffold design, as evidenced by fixed effects of design (a) and time (b).  
 
7.4. DISCUSSION AND CONCLUSIONS 
The aim of this study was to evaluate the effects of permeability on chondrogenesis in 
3D-designed scaffolds using chondrocytes or bone marrow stromal cells.  The first step 
was to design and fabricate scaffolds with controlled, reproducible, and significantly 
different permeability both alone and when infiltrated with collagen 1 hydrogel.  This 
ensured that throughout the study, whether the gel is present, or has degraded (as is 
suspected over time), there is a significant difference in the parameter we are evaluating.  
We were able to accomplish this goal by designing scaffolds with 1mm, spherical pores 
and 100% interconnectivity.  Experimental permeability measurements confirmed 
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computational permeability predictions for these designs: that significant difference 
exists between low, mid and high designs. 
 
3D-designed scaffolds were mechanically tested in stress-relaxation to evaluate their 
biphasic nature and load-bearing capacity.  Scaffolds showed the viscoelastic response 
inherent of native articular cartilage (see Chapter 5), but aggregate modulus values of 
these designs were higher than native tissue values.  Increased stiffness between 
implanted matrices and native tissue may cause fibrous tissue formation, elevated levels 
of strain in the adjacent cartilage, and acceleration of degeneration of the tissue.35   This 
suggests that another, less stiff material may be more suited for fabrication of these 
particular scaffold designs.  However, fabrication of scaffold designs with higher 
permeability would have continually lower aggregate moduli.  In this case, or for 
altogether different architectural design, PCL may provide aggregate modulus values 
within the range of cartilage.  Furthermore, for studying the effects of permeability, PCL 
is the ideal choice, as it does not degrade as quickly as other synthetic materials, such that 
permeability of the scaffold design does not change over time in culture. 
 
The effects of scaffold permeability on cell proliferation, cartilaginous matrix production, 
and expression of cartilage-specific genes were assessed for chondrocytes and bone 
marrow stromal cells.  Chondrocytes are a natural choice for cartilage tissue engineering, 
as they are the only cells present in native tissue.  However, harvesting of chondrocytes 
requires sacrifice of a healthy joint surface.  The cells are also difficult to culture, as they 
tend to dedifferentiate in monolayer.  For those reasons, other cell types, such as bone 
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marrow stromal cells and adipocyte-derived stem cells are continually explored for 
cartilage tissue engineering purposes.5, 36-43   
 
Chondrocytes encapsulated in collagen 1 hydrogel, seeded onto 3D scaffolds, and 
cultured in vitro appear more robust than BMSCs seeded under the same conditions.  
This research shows a steady increase in chondrocyte proliferation as measured at 0, 2, 
and 4 weeks, while there is a decrease in BMSC numbers between the zero time point 
and the 2 week time point.  Further studies would show a more detailed timeline for cell 
death. For chondrocytes, although there is an overall increase in cell number between the 
zero time point and 2 weeks, this doesn’t prove that all cells seeded survived, but rather 
that over two weeks cell proliferation was greater than any initial cell death.  For BMSCs, 
it could be possible that all cell death occurred during the first 24 hours or less, where 
after that, cell proliferation began.  Further work would provide further details into the 
robustness of these cell types in this environment, allowing clinicians to compensate for 
cell death when implanting such matrices.  
 
Results suggest that scaffold permeability affects the two cell types in opposite ways.  
Chondrocytes favor a lower permeable environment, that more closely mimics native 
cartilage conditions, when cultured in vitro on 3D scaffolds.  The lowest permeable 
design shows significant increases in cartilaginous matrix production at 4 weeks over 
higher permeable designs (66 µg sGAG/µg DNA and 513 µg sGAG/scaffold on low 
designs versus 17 µg sGAG/µg DNA and 112 µg sGAG/scaffold on high designs).  This 
data is also supported by an increase in aggrecan expression and an increase in the 
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“differentiation index” (collagen 2: collagen 1 expression) in correlation with decreased 
scaffold permeability.   One explanation for these results is described by the correlation 
between permeability and oxygen tension.  These changes can be attributed to decreases 
in oxygen tension (as reviewed in Chapter 4) in lower permeable designs that may induce 
production of cartilage specific components and structure of extracellular matrix.7   
 
Bone marrow stromal cells favor a higher permeable environment when cultured on 3D 
designed scaffolds in vitro in chondrogenic media.  This work shows an increase in 
cellular differentiation, as measured by the collagen 2: collagen 1 ratios, of 1.1 for each 
increasingly permeable scaffold design.  We also show that over time, BMSCs cultured 
on low and mid permeable scaffolds show no significant increase in differentiation index, 
whereas on the highest permeable scaffold collagen 2: collagen 1 mRNA expression 
significantly increased by a factor of 2.7 every 2 weeks.  These findings can be explained 
by the fact that BMSCs rely on nutrients from the media in order to differentiate.  This 
implies that in this model, cells relied on the diffusion of nutrients into the scaffold more 
than the desire to be in a low permeable environment that more closely mimics native 
tissue, for chondrogenic differentiation.   
 
Clinically, these findings have significant impact.  When filling a defect site, a scaffold is 
automatically subjected to a lower permeable environment than is seen in vitro, as its 
radial edges and bottom surface will be confined between native cartilage tissue and 
subchondral bone.  This data suggests that chondrocytes will be more suited for this type 
of repair system.  When replacing an entire articular surface, this data favors the use of a 
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less permeable design when using chondrocytes or a more permeable design when using 
bone marrow stromal cells.   
 
In conclusion, scaffold permeability has been shown to affect cartilaginous matrix 
production of chondrocytes and chondrogenic differentiation of bone marrow stromal 
cells on 3D scaffolds cultured in vitro.  This physical parameter is used as a quantitative 
description of mass transport variations caused by structural properties such as pore size, 
porosity, pore shape, and interconnectivity.  Although further studies should assess the 
effect of permeability in an in vivo orthotopic site, it should be deemed an important 
design consideration for scaffold tissue engineering. 
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SUMMARY AND FUTURE DIRECTIONS 
 
8.1 Summary 
Clinical treatment options to repair articular cartilage damage and deterioration are 
progressing to the incorporation of synthetic matrices alongside autologous chondrocyte 
implantation.  This work explores the mechanical properties and physical design 
considerations of potential matrices (scaffolds).  Solid freeform fabrication is used 
throughout this work to create highly reproducible scaffolds with precise structural 
features in order to explore the mechanical potential of 3D designed poly(ε-caprolactone) 
(PCL) and poly(glycerol sebacate) (PGS) scaffolds, and to examine the effects that a 
designed physical property, permeability, may have on cartilage tissue regeneration.   
 
The first part of this thesis explored the potential of PCL and PGS scaffolds to provide 
temporary mechanical function within a tissue defect by mimicking the stiffness of native 
cartilage.  We found that PCL mimics the viscoelastic nature of cartilage, however its 
stiffness properties cannot be significantly changed through changes in molecular weight 
(25 kDA – 50 kDa) or changes in melting temperature (110°C - 150°C).  Fabricated into 
the architectures explored in chapter 7, it has aggregate modulus (HA) values (low: 8.71 ± 
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1.06, mid: 5.76 ± 1.24, high: 3.09 ± 0.77) within the correct magnitude, but higher than 
the desired ranges of cartilage (0.5-1.0 MPa).  Future scaffolds made with a higher 
permeability or higher porosity design will have continually lower aggregate modulus 
values, and in such cases PCL could be used to match HA values to native cartilage.  We 
also quantified the differences in aggregate modulus of PCL mechanically tested at 
physiological temperatures versus room temperature, with increase of 150% (.2 MPa/°C) 
in modulus values for scaffolds tested at room temperature, demonstrating the importance 
of mimicking the in vivo environment during mechanical characterization for clinical 
applications.  Furthermore, we discovered that PCL contracts significantly in ethanol, due 
to compaction of the carbon chain or a change in bond structure when placed in a polar 
environment.  When designing custom scaffolds as mentioned earlier, it will be important 
to compensate for contraction of material seen in this study.  Computational up scaling of 
the scaffold implant could be applied to fix this change, or a less polar solvent, that does 
not cause contraction, can be investigated for removal of wax. Compensating for the 
contraction of PCL is also important in situations where the material will be placed in a 
polar in vivo environment. For instance, Yu et al.1   document contraction of PCL in 
bladder applications, where the material is in contact with urine.  
 
Poly(glycerol sebacate) has never been used for cartilage tissue engineering applications.  
In this work we characterized the changes in stiffness that can be created through 
variations in the molar ratio of glycerol: sebacic acid during polymer synthesis and 
through variations in the duration of curing.  Working with a material that’s intrinsic 
elastic properties can be altered enables fabrication of scaffolds with a wide range of 
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architectures (designed for optimal tissue regeneration) from one material, all of which 
will support in vivo loads.  We showed that although it does not mimic the viscoelastic 
properties of cartilage, the elastic component of PGS scaffolds, no matter what the 
architecture can be made to match generally accepted values for the elastic component of 
native cartilage (0.22 MPa – 0.45 MPa, corresponding to HA = 0.5 – 1.0 MPa, ν = 0.3) 
(Table 8.1).  Furthermore, we showed that chondrocytes seeded onto PGS produce sGAG 
quantities (29.64 ug sGAG/ug DNA vs. 33.00 ug sGAG/ug DNA on PCL) and cartilage 
specific gene expression (aggrecan: 1.67 vs. 1.74 on PCL and collagen 2: collagen 1 
20.91 vs 8.69 on PCL) similar to or better than that of cells cultured on PCL under the 
same conditions, proving their biocompatibility with the material for the first time.  
 
Throughout this work, we verify that finite element analysis can be used to predict the 
stiffness values of scaffold designs when bulk material properties are known.  As seen in 
Table 8.1, it can be used to predict modulus values of scaffold designs from a database of 
bulk material properties (such as PGS).  This technology can be used in the future to 
predict stiffness values of potential scaffold architectures or custom implant designs.   
Table 8.1.  Predicted tangent modulus values for low, mid and high permeable scaffold designs used 
in chapter 7 made from PGS characterized in chapter 6.  Highlighted cells are those scaffolds which 
fall within the ranges of native tissue elastic properties. 





 Low Permeable Design Mid Permeable Design High Permeable Design 
24  0.62 0.46 0.03 0.36 0.27 0.02 0.21 0.16 0.01 
48  0.81 0.60 0.11 0.47 0.35 0.06 0.28 0.21 0.04 
72  1.13 0.75 0.19 0.66 0.43 0.11 0.39 0.26 0.06 
  3:4 1:1 4:3 3:4 1:1 4:3 3:4 1:1 4:3 
  Molar Ratio (glycerol: sebacic acid) 
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The second goal of this work was to enhance cartilage tissue regeneration through 
providing optimal mass transport properties within the scaffold.  We found that scaffold 
permeability affects chondrogenesis of chondrocytes and bone marrow stromal cells in 
different ways.  Chondrocytes appear to prefer a less permeable scaffold environment, 
producing significantly more sGAG and increased expression of cartilage specific 
markers. At 2 weeks, there is a strong linear correlation between increasing permeability 
and decreasing sGAG content, and at 4 weeks, the lowest permeable design shows 
significant increases in sGAG content over both mid and high permeable designs (low: 
66.4 ug sGAG/ug DNA, mid: 19.8 ug sGAG/ug DNA, high: 17.1 ug sGAG/ug DNA).  
This is supported by collagen 2: collagen 1 ratios at 4 weeks (low: 12.9, mid: 7.5, high: 
2.6 normalized to GAPDH).  A lower permeable scaffold environment mimics the natural 
environment of native cartilage, where increases in permeability are correlated with 
disease and deterioration, and decreases in permeability with tissue depth correlate with a 
rise in proteoglycan content.{{343 Maroudas, 1968; }}  In tissue engineering, increases 
in scaffold permeability cause increases in oxygen levels, which have been shown to 
disturb the equilibrium of reactive oxygen species within the tissue, leading to 
deterioration of cartilage.  In support of decreased scaffold permeability enhancing 
chondrogenesis by chondrocytes, Malda et al. state that “low oxygen induces production 
of cartilage specific components and structure of the extracellular matrix.”2  
 
Bone marrow stromal cells (BMSCs) display the opposite trend, favoring a higher 
permeable environment for chondrogenic differentiation, as displayed through collagen 2: 
collagen 1 expression.  With increasing permeability, there is an increase of 1.1 in the 
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differentiation index for each scaffold design.  Over time the highest permeable design 
shows a significant increase of 2.7 in the differentiation index every two weeks, with the 
low design actually showing a decrease in collagen 2: collagen 1 expression. Unlike 
chondrocytes, which are already differentiated when they are seeded onto the scaffolds, 
BMSCs rely on nutrients and growth factors from the media in order to induce them 
down the chondrogenic lineage.  Therefore, this study shows that increased access to 
these induction factors is more important to these cells than mimicking the low 
permeable environment of native tissue.  
 
Previous studies demonstrate that there is no consensus on how structural design 
parameters affect cartilage tissue regeneration on 3D scaffolds.  In this work, we use the 
parameter of permeability to physically characterize the scaffold environment created by 
such structural properties.  It is our hope that this parameter and other physical 
parameters such as diffusivity can be used to better understand how scaffold 
environments affect tissue regeneration.   We believe that permeability may be the key to 
understanding differences seen in other studies.  
 
Combining the two goals presented in this work has significant impact from a design 
perspective.  It allows us to design scaffold architectures based solely on tissue in growth 
requirements, and then to choose processing parameters for a selected material that, when 
used to fabricate the chosen architecture, will create a scaffold effective stiffness that 
matches that of native tissue.  An overview of the results found in this work is illustrated 




Optimal scaffold for specific anatomic location based on target modulus 
and optimal permeability
Chondrocytes: Low permeable design made from ( 1:1 MR/24h cure) PGS
BMSCs: High permeable design made from (3:4 MR/72h ) PGS, or even 
higher permeability designs made from PCL
Bulk Material Properties and Scaffold 
Architecture determine Scaffold 
Mechanical Properties
PCL PGS



















Figure 8.1  Flowchart showing major conclusions of this dissertation (MR=molar ratio). 
 
8.2  Future Directions 
8.2.1 Exploiting the differences between PCL and PGS 
In the material characterization portion of this work, we discovered a number of 
interesting material differences between PCL and PGS.  Because both of these materials 
can be used to make identical 3D scaffolds through SFF, their material differences could 
be used in order to study the effects of these properties on cartilage tissue regeneration.  
A comparative study between PGS and PCL scaffolds could reveal the influence that 
hydrophobicity has on cellular interactions, and therefore, cartilage tissue regeneration.  
Scaffolds made out of these two materials could also be used to explore the importance of 
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mimicking viscoelasticity in a load bearing model, revealing the extent to which this 
unique property should be pursued for optimal tissue regeneration and integration.   
 
8.2.2 Osteochondral Scaffold from PCL and PGS 
Previous work not included in this dissertation developed the use of selective laser 
sintered (SLS) PCL for bone applications.3   With SLS PCL  mechanical properties that 
fall within the lower ranges of trabecular bone, and PGS elastic properties that can be 
made to match those of native cartilage, these two materials could be combined to create 
an osteochondral scaffold.  Further work in this area could assess the effects of closed or 
open interfaces between the two polymer sections, which would presumable influence 
cell-cell contacts between osteoblasts (or other bone-producing cells)  and chondrocytes 
(or other cartilage-producing cells).   
   
8.2.3 Permeability effects in other models 
Now that low, mid, and high permeable designs can be fabricated and have been fully 
characterized to show significant difference between groups, these designs can be 
extended to study the effects of permeability on other cells for cartilage tissue 
engineering or for other tissue types all together.  Preliminary studies have already begun 
using adipocyte-derived stem cells for cartilage purposes.  Pre-adipocytes seeded onto the 
high permeable scaffold designs differentiated into morphologically rounded cells and 
produced some sGAG when cultured in media containing BMP6 (essential for 
differentiation in this study).  Xu et al.4  show that lower oxygen tensions (2%) promotes 
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early chondrogenesis in mouse pre-adipocytes.  Further work to explore the effects of 
scaffold permeability on these cell types would be a logical next step.   
 
Work has also begun exploring the effects of permeability on bone tissue regeneration 
using the low and high permeable designs created in this work.  Preliminary work done 
by Annie Mitsak shows that bone is formed within the pores of all scaffold designs, and 
an outer bone shell surrounds the exterior of the scaffolds.  Total bone produced on high 
permeability designs is greater than that produced on low permeability designs, but once 
total bone volume is normalized to the total amount of pore space available, significant 
differences are not present.  Because higher permeability designs do allow for more bone 
growth overall, they may be a better choice for bone tissue engineering, however, 
increased permeability correlates with decreased initial mechanical properties, so further 
analysis that explores initial mechanical properties, rate of bone regeneration (and 
mechanical properties of the regenerated bone), and rate of scaffold degradation, all with 
regards to permeability can be explored.   
 
8.2.4 Effects of permeability in more complex in vitro and in vivo environments 
Permeability has an effect on the loading environment of scaffolds, which has been 
shown to have an effect on cartilage regeneration.5-7   Further studies on the effects of 
permeability on tissue regeneration should extend into in vitro systems that generate load 
on the scaffolds.  Permeability, as demonstrated, affects diffusion of growth factors into 
scaffolds.  The complex cocktail of growth factors expressed in a synovial environment is 
not recapitulated in vitro.  Testing of these scaffolds in an orthotopic site would provide 
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further impacts that designed scaffold permeability has on cartilage tissue engineering.  
Implantation in an orthotopic site would also take into account confinement of the radial 
edges and bottom of the scaffold as occurs in a clinical setting.     
 
8.2.5  Exploring oxygen tension hypothesis 
As hypothesized, chondrocyte favoritism of a low permeable environment may be due to 
lower oxygen levels created within the scaffold.  In order to confirm this, work should be 
done to experimentally measure the differences in oxygen tension between scaffold 
designs.  Although mathematical programs have been established to predict oxygen 
tensions within a scaffold, to the best of our knowledge, actual oxygen tensions within 
scaffolds has not been measured.  Perhaps a device could be modeled after the device 
used by Woodhouse that measures the oxygen tension inside of bone.8  This hypothesis 
can be further explored through quantitative assessment of histology through 
histomorphometric analysis, which would enable measurement of sGAG production at 
different areas of a scaffold, with the assumption that oxygen levels in the interior are 
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APPENDIX A: POLY(ε-CAPROLACTONE) MELT CASTING PROTOCOL 
 
Name of Procedure: Melt-Casting PCL scaffolds 
Prepared by: Jessica Kemppainen  
Location: This procedure is performed in LBME 2420 
Hazards: none  
Engineering Controls: none 
Protective equipment: Use latex gloves when working with Ethanol, or to keep your hands protected from 
hot PCL. 
Waste disposal: regular trash  
 
Melt-Cast PCL Scaffold Fabrication 
 
1. Assemble Teflon Mold 
 You will periodically need to replace the Teflon tape on the screws. This assures that air won’t be 
pulled into the PCL during high vacuum. 
 
2. Place 6 pellets of PCL (CAPA6400) into each Teflon mold hole. 
3. Coat outer cracks of mold with vacuum grease. Again, this assures that air won’t be pulled into the 
polymer. 
4. Place mold + PCL into the oven at 115°C. Close door, close vent and gas knobs, completely open 
vacuum knob. 
5. Turn on vacuum pump. Assure that swagelock arrow is pointed toward the tube leading to the 
oven. 
6. Leave in for 2 hours. 
7. After 2 hours, close the vacuum knob, and turn off the vacuum pump. Open the vent knob, and 
slowly release the vacuum from the oven. 
8. Remove mold+PCL from oven and let sit on cool countertop for 4m30s 
9. Carefully press green wax mold into PCL. 
10. Let sit overnight to cool and cure. (storage: on counter in Teflon mold) 
 
Scaffold Processing 
1. Disassemble Teflon mold 
2. Press green wax+PCL out using alan wrench. 
3. Trim excess PCL from the top and bottom of the green wax mold, using a razor blade. 
4. Place green wax+PCL into a 50ml conical tube with ~40ml 100% EtOH. 
5. Place on vortex for ~2hours (until all or most of the green wax is dissolved) 
6. Drain green EtOH into waste bottle, and dump scaffolds onto a paper towel. 
7. While the scaffolds are still damp, carefully remove the outer layer of excess PCL with your 
hands. 
8. Place the scaffolds back on the vortex in 100% EtOH to remove anymore green wax (should take 
~30min-1 hour depending on how much wax remains) 
9. Remove scaffolds from EtOH, and place on paper towel (label the paper towel with the design 
name) 
10. After scaffolds completely dry, use a fresh razor blade to trim them to a height of 3 unit cells 
(storage after step 10: in appropriately labeled weight dish on counter) 
 
The following also serve as my “quality control” elimination steps. 
11. Clean pores of scaffolds with cleaning wire.  
12. Place scaffolds in 100% EtOH on spinner overnight. 









Scaffold fits snuggly into 
chamber and is held in 











APPENDIX B: PERMEABILITY CHAMBER PROTOCOL 
 
Name of Procedure: Permeability Chamber Measurements 
Prepared by: Jessica Kemppainen 
Location: This procedure is performed in LBME 2411C using the permeability chamber beside the sink 
Hazards: none  
Engineering Controls: none 
Protective equipment: none 
Waste disposal: regular trash  
 

















































One hour prior to testing 
1. Hook up “water flow in” hose to the sink faucet. 
2. Make sure that white clip on hose is CLOSED. 
3. Turn on cold water so that flow meets sharpie dot on reservoir (see Jessica). 
 
Testing-Setup & Calibrated Mass Flow 
4. Turn on scale. 
5. On SEG-IMAGING, open Labview, File=permeability_meters. 
6. Change OPERATION to “replace or create” 
7. In FILE PATH click on the folder and create a new folder for your experiments 
8. In FILE PATH, change the file name (now being saved in your folder) to MASSFLOW1 
9. Hook up permeability chamber to reservoir-use needle nose pliers to tighten. 
10. Set 500 ml plastic bottle on scale with tube from chamber centered into bottle. 
11. Unclip white clip so that water begins flowing through the chamber. 
12. Immediately after water begins flowing into bottle, click on the  in lab view (top left corner) to 
RUN. 
Note:on the first flow, you will want to pinch out any air bubbles you see in the tubes before taking a 
measurement) 
13. Watch weight on scale or in labview-once it reaches 350g-immediately hit the red octagon stop 
(NOT THE “STOP” button), then immediately reclip the white clip.Do not let the scale see a 
load of more than 400g.  
14. Empty the plastic bottle into the sink. 
15. Repeat starting at step 8,  renaming now as MASSFLOW2 
16. Repeat mass flow 5 times. 
17. Average your results in excel, column 3: average the entire column, then average the averages of 
all five runs. 
18. Type your average mass flow into the “Cal Mass Flow” box in labview. 
 
Testing your samples 
19. Measure height of sample: input into “sample length” box in labview 
20. For Jessica’s chamber, input .000032 into the “x-sec area” box. This is the cross sectional area of 
the chamber, which should also be the cross sectional area of your scaffold. 
21. Rename file in “File Path” as specimen name 
22. Unscrew chamber from reservoir using needle nosed pliers 
23. Place sample into top of chamber carefully. There is a nylon filter (see diagram) that is glued to 
the edges, and WILL come out if you press too hard.  I usually get the specimen situated and level 
within the tunnel and then tap it in using the chopsticks sitting beside the apparatus. 
24. Tighten the chamber back onto the hose using needle nosed pliers 
25. Place plastic bottle back on scale underneath hose. 
26. Unclip the white clip 
27. Just after water begins flowing into bottle, click on the  in lab view (top left corner) to RUN. 
28. Watch weight on scale or in labview-once it reaches 350g-immediately hit the red octagon stop 
(NOT THE “STOP” button), then immediately reclip the white clip.Do not let the scale see a 
load of more than 400g.  
29. Empty the plastic bottle into the sink. 
30. Remove your specimen from the chamber by unscrewing the chamber from the hose, placing 
chamber upside down on paper towel, and then blowing a short/light blast of air (using the 
DUSTOFF canister) into the tubing. This should blow your scaffold out. Do not stick anything 
into the chamber to get your scaffold out, as you will puncture the filter. 
31. Repeat for rest of specimens: start at step 19. 
 
Afterwards 
Drain water from upper reservoir and disconnect tubing from faucet. 
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APPENDIX C: PROTOCOL FOR CONFINED COMPRESSION (STRESS-RELAXATION) 
 
Name of Procedure: Stress-relaxation confined compression testing 
Prepared by: Jessica Kemppainen  
Location: This procedure is performed in LBME 2420 
Hazards: Load cells used in this procedure are extremely fragile. Do NOT overload them. 
Engineering Controls: none 
Protective equipment: safety glasses, close-toed shoes 
Waste disposal: none 
 
** Do not bump or lean on the table that the MTS sits on during testing** 
 
30 minutes prior to testing 
1. Unscrew the red safety button on the MTS machine. 
2. Turn on the MTS machine with the keypad by pressing the ‘| ‘ button.  The program will not work 
correctly unless the machine is turned on before TestWorks4 is opened. 
3. Open TestWorks4. 
4. Enter the appropriate user login name. 
5. Make sure the appropriate load cell is attached – we have 4 load cells (10N, 50N, 30kN and 
500N). This will depend on the material that your scaffold is made from. (Note:I have used the 
500N load cell for PCL and the 50N load cell for PGS with the acrylic chamber.  If you think your 
sample will exert high enough loads to switch to the 30kN load cell, you may want to consider 
machining a stainless steel chamber.) 
6. Setup the device: attach the porous indenter to the top load cell, and attach the fixed lower platen.  
Calibrate and Print General History: 
a. Select Tools → Calibrate and click the Calibrate button to calibrate the machine.  Note:  
If a device error occurs, shut down the MTS machine and the computer.  Turn the MTS 
machine on, and then turn the computer on and open TestWorks4.  This should resolve 
the error. 
b. Select Tools → Calibrate → History → Print General History for the 500N load cell.  
Paste the General History in the MTS logbook. 
7. Soak porous part of porous indenter in media for 30 minutes prior to testing by filling the chamber 
with media (or the solution you will use during tests) and lowering the indenter into the chamber. 
8. (For thermal-controlled environment) Plug the thermal-controlling HyWatt (surrounding the 
exterior of the acrylic chamber) into the thermo-controller, and set it to 42°C. This will maintain 
the liquid you put within the chamber at 37°C. 
 
Testing  
9. Select Method → Open Method → “creep, relaxation and one cycle hysterisis 
package” ”compression” ”relaxation” ”JMK MTS Relax Compress 2 (1 ramp)” 
10. Change the platen separation value in test inputs to 25 mm (or to the height of your chamber if you 
have designed your own) 
11. Change test Procedue to 1. Set Platen Separation 
12. Hit the large green arrow (RUN) 
13. Enter Sample ID: date_intials_title of project (A “Sample” =  all specimens tested this day), OK 
14. Enter Specimen ID: name of specimen to test (A “specimen” = one scaffold), OK 
15. Follow on screen instructions on how to align confined chamber with indenter 
16. Hit OK: at this point the indenter will lower and find the bottom of the chamber and then raise 
25mm up. Watch for double green arrows in lower right corner to change to a red square to signify 
the end of “platen separation”. 
17. You can now move the confined chamber to place your specimen gently into the bottom. 
Remember that in stress relaxation, load history is important, so avoid unnecessary loads on your 
specimen. Consider using the plunger of an insulin syringe. 
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18. Change the preload value. I suggest using .25 for materials such as PCL or .02 for materials such 
as POC or PGS. Essentially, you want the preload to just find the top of your specimen without 
placing any extra load onto it. 
19. Change test procedure to 0: Test 
20. *Hit the large green arrow to run the test 
21. Follow onscreen instructions: again, these instructions inform you how to align the porous 
indenter with the confined compression chamber. OK. 
22. “TEST IS ABOUT TO BEGIN”-hit OK on this screen to begin test. Note: test will take about 1 h. 
 
After Test Completes 
23. Hit OK on screen that appears. This will raise the crosshead. 
24. File save sample-When naming the data, use the following format ‘date_user initials_sample 
description’. For example, 05102005_CLF_4wkPCLsubq. This saves the batch of specimens as a 
.msm file, which can only be read by Testworks. Save your data after each specimen. It is very 
important to do this after EVERY specimen tested. If you don’t do this, and the computer crashes 
or the power goes out, you will lose all of your data. 
25. To start next specimen go back up to *. You do not need to do a platen separation for each 
specimen. You must do it for each new day of testing. 
 
At the end of the day 
26. Export each Specimen Data: On Review tab, select specimen 1 by highlighting it in the upper left 
hand box.  Select File → Export → Specimen.  This file contains the raw data for each specimen-
should be exported as a .txt file. It will be named as the “sample name” so you must go in and 
change this name before exporting the next specimen, or it will be written over.  Go to jessmw 
folder, Export, sort by date and it will appear at the top. Add the specimen ID to the end of the file 
name. Repeat for each specimen. 
27. Export Sample Data: Select File → Export → Sample.  This file contains height data for all 
specimens tested under one sample name (one day), should be exported as a .txt file. You only 
need to do this once. 
28. Raise crosshead on MTS 
29. Clean out porous indenter with RO H2O followed by blowing air through it to completely dry out 
the indenter. Unscrew indenter from crosshead and wrap in kimwipe to store in the sample box it 
belongs in. 
30. Close out of testworks 
31. Power down the MTS, and engage the red safety button. 
 
Data Analysis 
32. Open .txt files in Excel.  Select ‘delimited’, select ‘comma’ separation, and hit okay. DO NOT 
USE THE STRESS COLUMN. Calculate the stress yourself. 
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APPENDIX D: PROTOCOL FOR MEASURING DNA CONTENT 
 
Name of Procedure: Hoechst 33258 protocol for measuring DNA content 
Prepared by: Jessica Kemppainen  
Location: This procedure is performed in LBME 2420 
Hazards: Hoechst 33258 is toxic. Please read MSDS carefully before use.  
Engineering Controls: none 
Protective equipment: safety glasses, gloves 
Waste disposal: Hoechst waste bottle 
 
1.  Make 1X TNE working solution 
 5 mls 10X TNE + 45 mls dH2O 
 
2.  Dilute Hoechst 
 a. 495 ul 1X TNE + 5 ul 10mg/ml stock in 1.5 ml tube (= 0.1mg/ml) 
 b. 4.99 mls 1X TNE + 10 ul a in 15 ml tube wrapped in aluminum foil (= 2X solution, 100 ng/ml, 
 make fresh) 
 
3. Make standards 
 Calf thymus DNA (CT DNA) = 250 ul 1X TNE to vial shipped (as stated in directions from 
 company, Sigma, #D0805) = 1 mg/ml solution (can store at 4°C for 3 months) 
 
 Dilute 1mg/ml CT DNA to 100 µg/ml stock: 
  100 ul CT DNA from 3 + 900 ul 1X TNE, filter 
  
 Standards: For 10 – 500 ng/ml 
 Start with 10 ul of CT DNA (100 µg/ml) in 990 ul 1X TNE (= 100 ng in 100 ul) 
  Dilute 2X in 1X TNE 6 times, getting standards down to 1.562 ng (in 100 ul)  
 
4.  Measuring DNA content of samples and standards 
 Add 100 ul/standard and 100 ul/sample to wells in a 96 well plate (duplicates or triplicates 
 suggested) 
 
 Add 100 ul diluted Hoechst (from 3) 
 
 Incubate at room temperature for 5 minutes  
 
 Read: excitation: 355nm, emission: 460nm (Fluoroskan Ascent FL, Thermo, Waltham, MA) 
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APPENDIX E: PROTOCOL FOR MEASURING S-GAG CONTENT 
 
Name of Procedure: Dimethylmethylene Blue (DMMB) Assay for measuring s-GAG content 
Prepared by: Jessica Kemppainen (modified from Elly Liao) 
Location: This procedure is performed in LBME 2420 
Hazards: none.  
Engineering Controls: none 
Protective equipment: gloves 
Waste disposal: DMMB waste bottle 
______________________________________________________________________________________ 
 
1.  Mix DMMB reagent: 
 16 mg 1,9 dimethyl-methylene blue dye (Sigma, # 341088) 
 3.04 g Glycine 
 2.37 g NaCl 
 95 ml 0.1M HCl 
 In 1 liter of diH2O 
 Bring to pH of 3.0 
 
2.  Make standards from shark chondroitan-6-sulfate (Sigma, # C4384) 
 Starting with a stock concentration of 1 µg/ul 
 Add 100 ul stock + 900 ul Millipore H2) (= .1 µg/ul) 
 Dilute 2X 6 times down to .0015 µg/ul 
 
3.  Measuring sGAG content of samples and standards 
 Add 20 ul of standards or sample (well-mixed, centrifuged at 14,000, 10 min, 4°C if you need to 
 remove polymer residue) 
  
 Turn off most of the lights in your working environment, as DMMB is extremely light sensitive.  
 
 Add 200ul DMMB to each well using multi-channel pipettor.  
 
 Read immediately on a plate reader (MultiSkan Spectrum, Thermo, Waltham, MA) at 525 nm. 
 
